<?xml version="1.0" encoding="UTF-8"?>
<CustomObjectTranslation xmlns="http://soap.sforce.com/2006/04/metadata">
    <caseValues>
        <plural>false</plural>
        <value>Beoordeling</value>
    </caseValues>
    <caseValues>
        <plural>true</plural>
        <value>Beoordelingen</value>
    </caseValues>
    <fields>
        <label>Account</label>
        <name>Account__c</name>
        <relationshipLabel>Beoordelingen</relationshipLabel>
    </fields>
    <fields>
        <help><!-- To what extent does the prescriber/non-prescriber assess the dose reduction schedule to manage toxicities? --></help>
        <label><!-- Assess dose reduction to mng toxicities? --></label>
        <name>Assess_dose_reduction_BMS__c</name>
        <picklistValues>
            <masterLabel>Consistently assesses</masterLabel>
            <translation><!-- Consistently assesses --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Does not assess</masterLabel>
            <translation><!-- Does not assess --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Infrequently assesses</masterLabel>
            <translation><!-- Infrequently assesses --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Proactively assess for IXEMPRA toxicities</masterLabel>
            <translation><!-- Proactively assess for IXEMPRA toxicities --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- If HCP uses YERVOY, the HCP assesses tumor progression for YERVOY patients? --></help>
        <label><!-- Assesses tumor progression? --></label>
        <name>Assesses_tumor_progression_BMS__c</name>
        <picklistValues>
            <masterLabel>Before 12 weeks and changes YERVOY regimen based on the results of these tests</masterLabel>
            <translation><!-- Before 12 weeks and changes YERVOY regimen based on the results of these tests --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Before 12 weeks, but doesn&apos;t change YERVOY regimen based on these scans</masterLabel>
            <translation><!-- Before 12 weeks, but doesn&apos;t change YERVOY regimen based on these scans --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Only after 12 weeks</masterLabel>
            <translation><!-- Only after 12 weeks --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Only after 12 weeks and every 4 weeks up to 24 and then every three months thereafter as per label</masterLabel>
            <translation><!-- Only after 12 weeks and every 4 weeks up to 24 and then every three months thereafter as per label --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Does this physician treat at least one or more CML patients per year? --></help>
        <label><!-- At least one CML patient per year? --></label>
        <name>At_least_one_CML_patient_per_year_BMS__c</name>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Does prescriber continue Avastin use across multiple lines of therapy? --></help>
        <label><!-- Avastin across multiple therapy lines? --></label>
        <name>Avastin_across_multiple_therapies_BMS__c</name>
        <picklistValues>
            <masterLabel>Occasionally continues Avastin across lines of therapy</masterLabel>
            <translation><!-- Occasionally continues Avastin across lines of therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regularly continues Avastin across 2 lines of therapy</masterLabel>
            <translation><!-- Regularly continues Avastin across 2 lines of therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regularly continues Avastin across 3+ lines of therapy</masterLabel>
            <translation><!-- Regularly continues Avastin across 3+ lines of therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Uses Avastin in single line of therapy if at all</masterLabel>
            <translation><!-- Uses Avastin in single line of therapy if at all --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Is prescriber aware of reimbursement assistance programs? --></help>
        <label><!-- Aware of rmbrsmnt assistance programs? --></label>
        <name>Aware_of_reimbursement_assistance_BMS__c</name>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- BMS Code ID --></label>
        <name>BMS_Code_ID__c</name>
    </fields>
    <fields>
        <help><!-- Approximately how many unique metastatic Breast Cancer patients per year does the prescriber treat with chemotherapy? --></help>
        <label><!-- Breast Cancer ptnts trtd w/ chemotherapy --></label>
        <name>Breast_Cancer_ptnts_chemotherapy_BMS__c</name>
    </fields>
    <fields>
        <help>Hoe groot is de kans dat de KOL patiëntprofieldocumenten zal gebruiken?</help>
        <label>Patiëntprofielen CC</label>
        <name>CC_Patient_Profiles__c</name>
        <picklistValues>
            <masterLabel>Somewhat Likely</masterLabel>
            <translation>Enigszins waarschijnlijk</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unlikely</masterLabel>
            <translation>Onwaarschijnlijk</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Very Likely</masterLabel>
            <translation>Zeer waarschijnlijk</translation>
        </picklistValues>
    </fields>
    <fields>
        <help>Hoe groot is de kans dat de KOL onderzoeksresultaten voor Cholecap zal gebruiken in bezoeken met collega&apos;s?</help>
        <label>Onderzoekstoepassing CC</label>
        <name>CC_Study_Leverage__c</name>
        <picklistValues>
            <masterLabel>Somewhat Likely</masterLabel>
            <translation>Enigszins waarschijnlijk</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unlikely</masterLabel>
            <translation>Onwaarschijnlijk</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Very Likely</masterLabel>
            <translation>Zeer waarschijnlijk</translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Channel --></label>
        <name>Channel_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Commercial Only</masterLabel>
            <translation><!-- Commercial Only --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Commercial and MMA</masterLabel>
            <translation><!-- Commercial and MMA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Hospital/Specialty GPO</masterLabel>
            <translation><!-- Hospital/Specialty GPO --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MMA only</masterLabel>
            <translation><!-- MMA only --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Managed Medicaid</masterLabel>
            <translation><!-- Managed Medicaid --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Medicare Part B Carrier</masterLabel>
            <translation><!-- Medicare Part B Carrier --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PBM</masterLabel>
            <translation><!-- PBM --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Specialty Pharmacy</masterLabel>
            <translation><!-- Specialty Pharmacy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>State Medicaid</masterLabel>
            <translation><!-- State Medicaid --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VA/DOD</masterLabel>
            <translation><!-- VA/DOD --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- What percentage of the business (payer) mix in the office is commercial? --></help>
        <label><!-- Commercial --></label>
        <name>Commercial_BMS__c</name>
        <picklistValues>
            <masterLabel>0-10%</masterLabel>
            <translation><!-- 0-10% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>11-20%</masterLabel>
            <translation><!-- 11-20% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>21-30%</masterLabel>
            <translation><!-- 21-30% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>31-40%</masterLabel>
            <translation><!-- 31-40% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>41-50%</masterLabel>
            <translation><!-- 41-50% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>51-60%</masterLabel>
            <translation><!-- 51-60% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>61-70%</masterLabel>
            <translation><!-- 61-70% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>71-80%</masterLabel>
            <translation><!-- 71-80% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>81-90%</masterLabel>
            <translation><!-- 81-90% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>91-100%</masterLabel>
            <translation><!-- 91-100% --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help>Hoe actief is deze KOL in de lokale gezondheidszorg?</help>
        <label>Community-activiteit</label>
        <name>Community_Activity__c</name>
        <picklistValues>
            <masterLabel>Not Active</masterLabel>
            <translation>Niet actief</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Slightly Active</masterLabel>
            <translation>Enigszins actief</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Somewhat Active</masterLabel>
            <translation>Matig actief</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Very Active</masterLabel>
            <translation>Zeer actief</translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- How does the treatment team member continue with ERBITUX? --></help>
        <label><!-- Continue with ERBITUX? --></label>
        <name>Continue_with_ERBITUX_BMS__c</name>
        <picklistValues>
            <masterLabel>Occasionally uses ERBITUX until progression or unacceptable toxicity</masterLabel>
            <translation><!-- Occasionally uses ERBITUX until progression or unacceptable toxicity --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regularly continues ERBITUX until disease progression or unacceptable toxicity</masterLabel>
            <translation><!-- Regularly continues ERBITUX until disease progression or unacceptable toxicity --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regularly discontinues ERBITUX early due to rash or when stopping chemo</masterLabel>
            <translation><!-- Regularly discontinues ERBITUX early due to rash or when stopping chemo --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Does this prescriber differentiate between ERBITUX and Vectibix? --></help>
        <label><!-- Differentiate btw ERBITUX and Vectibix? --></label>
        <name>Differentiate_ERBITUX_and_Vectibix_BMS__c</name>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes (Prefers Vectibix)</masterLabel>
            <translation><!-- Yes (Prefers Vectibix) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes (prefers ERBITUX)</masterLabel>
            <translation><!-- Yes (prefers ERBITUX) --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Does your facility allow you to distribute branded patient education materials? --></help>
        <label><!-- Distribute branded ptnt ed. materials? --></label>
        <name>Distribute_branded_ptnt_ed_BMS__c</name>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Does prescriber most closely follow? --></label>
        <name>Does_prescriber_most_closely_follow_BMS__c</name>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NCCN</masterLabel>
            <translation><!-- NCCN --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other guidance</masterLabel>
            <translation><!-- Other guidance --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Pathway</masterLabel>
            <translation><!-- Pathway --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reimbursement</masterLabel>
            <translation><!-- Reimbursement --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Does the prescriber recycle taxans? --></label>
        <name>Does_the_prescriber_recycle_taxans_BMS__c</name>
        <picklistValues>
            <masterLabel>Almost always</masterLabel>
            <translation><!-- Almost always --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Almost never</masterLabel>
            <translation><!-- Almost never --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Frequently</masterLabel>
            <translation><!-- Frequently --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Infrequently</masterLabel>
            <translation><!-- Infrequently --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not Applicable</masterLabel>
            <translation><!-- Not Applicable --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Sometimes</masterLabel>
            <translation><!-- Sometimes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Does the prescriber treat CRC? --></label>
        <name>Does_the_prescriber_treat_CRC_BMS__c</name>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Increased interest in tumor type</masterLabel>
            <translation><!-- Increased interest in tumor type --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Specialist</masterLabel>
            <translation><!-- Specialist --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes (normal level)</masterLabel>
            <translation><!-- Yes (normal level) --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Does MedOnc use ERBITUX in loco regionally advanced disease? --></help>
        <label><!-- ERBITUX: Locoregioanlly Advanced Disease --></label>
        <name>ERBITUX_Locoregioanlly_Advanced_BMS__c</name>
        <picklistValues>
            <masterLabel>Almost Always</masterLabel>
            <translation><!-- Almost Always --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Almost Never</masterLabel>
            <translation><!-- Almost Never --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Frequently</masterLabel>
            <translation><!-- Frequently --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Infrequently</masterLabel>
            <translation><!-- Infrequently --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not Applicable</masterLabel>
            <translation><!-- Not Applicable --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Sometimes</masterLabel>
            <translation><!-- Sometimes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Relative to platinum therapies, how does this physician perceive the efficacy of ERBITUX in the treatment of appropriate LRD SCCHN? --></help>
        <label><!-- ERBITUX perceived efficacy - LRD SCCHN --></label>
        <name>ERBITUX_perceived_efficacy_LRD_SCCHN_BMS__c</name>
        <picklistValues>
            <masterLabel>Exclusively uses Platinum+RT in eligible LRD patients</masterLabel>
            <translation><!-- Exclusively uses Platinum+RT in eligible LRD patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Typically uses ERBITUX+RT appropriately across LRD patients</masterLabel>
            <translation><!-- Typically uses ERBITUX+RT appropriately across LRD patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Uses ERBITUX+RT in patients eligible but high rise (ex. Low PS, elderly, comorbidities)</masterLabel>
            <translation><!-- Uses ERBITUX+RT in patients eligible but high rise (ex. Low PS, elderly, comorbidities) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Uses ERBITUX+RT only in patients who are clearly platinum-ineligible</masterLabel>
            <translation><!-- Uses ERBITUX+RT only in patients who are clearly platinum-ineligible --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Does MedOnc use ERBITUX in recurrent / metastatic desease? --></help>
        <label><!-- ERBITUX: recurrent/metastatic desease? --></label>
        <name>ERBITUX_recurrent_metastatic_desease_BMS__c</name>
        <picklistValues>
            <masterLabel>Almost always</masterLabel>
            <translation><!-- Almost always --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Almost never</masterLabel>
            <translation><!-- Almost never --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Frequently</masterLabel>
            <translation><!-- Frequently --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Infrequently</masterLabel>
            <translation><!-- Infrequently --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Sometimes</masterLabel>
            <translation><!-- Sometimes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- How does the HCP ensure save management of YERVOY? --></help>
        <label><!-- Ensure Safe Management of YERVOY? --></label>
        <name>Ensure_Safe_Management_of_YERVOY_BMS__c</name>
        <picklistValues>
            <masterLabel>Active involvement of Patient Educators</masterLabel>
            <translation><!-- Active involvement of Patient Educators --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Follow REMs protocols</masterLabel>
            <translation><!-- Follow REMs protocols --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Fully trained staff on YERVOY</masterLabel>
            <translation><!-- Fully trained staff on YERVOY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other internal systems to manage safety</masterLabel>
            <translation><!-- Other internal systems to manage safety --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Use of Patient Materials</masterLabel>
            <translation><!-- Use of Patient Materials --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Does customer believe that the current body of data is sufficient evidence to prescribe a 2nd Generation TKI over Gleevec in 1st line? --></help>
        <label><!-- Suff evidence to prescribe 2nd Gen TKI? --></label>
        <name>Evidence_to_prescribe_2nd_Gen_TKI_BMS__c</name>
        <picklistValues>
            <masterLabel>No I would need longer term follow-up to prescribe a 2nd Gen. TKI in 1st line</masterLabel>
            <translation><!-- No I would need longer term follow-up to prescribe a 2nd Gen. TKI in 1st line --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes the current data is sufficient evidence</masterLabel>
            <translation><!-- Yes the current data is sufficient evidence --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Quantify the level of access for this prescriber based on number of face to face calls that can be delivered per year. --></help>
        <label><!-- Face-to-face calls per year --></label>
        <name>Face_to_face_calls_per_year__c</name>
        <picklistValues>
            <masterLabel>0</masterLabel>
            <translation><!-- 0 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>1</masterLabel>
            <translation><!-- 1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>10</masterLabel>
            <translation><!-- 10 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>11</masterLabel>
            <translation><!-- 11 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>12</masterLabel>
            <translation><!-- 12 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>13</masterLabel>
            <translation><!-- 13 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>14</masterLabel>
            <translation><!-- 14 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>15</masterLabel>
            <translation><!-- 15 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>16</masterLabel>
            <translation><!-- 16 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>17</masterLabel>
            <translation><!-- 17 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>18</masterLabel>
            <translation><!-- 18 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>2</masterLabel>
            <translation><!-- 2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>3</masterLabel>
            <translation><!-- 3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>4</masterLabel>
            <translation><!-- 4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5</masterLabel>
            <translation><!-- 5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>6</masterLabel>
            <translation><!-- 6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>7</masterLabel>
            <translation><!-- 7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>8</masterLabel>
            <translation><!-- 8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>9</masterLabel>
            <translation><!-- 9 --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Can the prescriber articulate/how familiar are they with the two step (20%) dose reduction schedule for certain toxicities? --></help>
        <label><!-- Familiar with 2-step dose reduction? --></label>
        <name>Familiar_with_2_step_dose_reduction_BMS__c</name>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Sometimes familiar</masterLabel>
            <translation><!-- Sometimes familiar --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unaware</masterLabel>
            <translation><!-- Unaware --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Vaguely Familiar</masterLabel>
            <translation><!-- Vaguely Familiar --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Very familiar</masterLabel>
            <translation><!-- Very familiar --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- First Health Plan --></label>
        <name>First_Health_Plan_BMS__c</name>
        <picklistValues>
            <masterLabel>Aetna</masterLabel>
            <translation><!-- Aetna --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BCBS</masterLabel>
            <translation><!-- BCBS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Cigna</masterLabel>
            <translation><!-- Cigna --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>United Health Care</masterLabel>
            <translation><!-- United Health Care --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Well Point / Anthem</masterLabel>
            <translation><!-- Well Point / Anthem --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- How would you categorize the way this physician administers ERBITUX+RT in the SCCHN LRD? --></help>
        <label><!-- How does prscrbr administer ERBITUX+RT? --></label>
        <name>How_does_prscrbr_administer_ERBITUX_BMS__c</name>
        <picklistValues>
            <masterLabel>Does not know how to appropriately determine difference between mild/moderate and severe EGFR rash and infusion reactions</masterLabel>
            <translation><!-- Does not know how to appropriately determine difference between mild/moderate and severe EGFR rash and infusion reactions --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Is unaware of dosing modifications for severe EGFR rash and infusion reactions</masterLabel>
            <translation><!-- Is unaware of dosing modifications for severe EGFR rash and infusion reactions --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactively responds to mild/moderate reactions with dose modifications</masterLabel>
            <translation><!-- Reactively responds to mild/moderate reactions with dose modifications --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Understands all dose modifications for toxicities and appropriately dose modifies for severe EGFR rash and for infusions reactions</masterLabel>
            <translation><!-- Understands all dose modifications for toxicities and appropriately dose modifies for severe EGFR rash and for infusions reactions --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- If HCP uses YERVOY, the HCP infuses YERVOY? (Choose all that apply) --></help>
        <label><!-- How does the HCP infuse YERVOY? --></label>
        <name>How_does_the_HCP_infuse_YERVOY_BMS__c</name>
        <picklistValues>
            <masterLabel>3mg/kg dose used</masterLabel>
            <translation><!-- 3mg/kg dose used --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>If 3/4 doesn&apos;t resolve on w/hold - stops</masterLabel>
            <translation><!-- If 3/4 doesn&apos;t resolve on w/hold - stops --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Once every three weeks for 4 doses</masterLabel>
            <translation><!-- Once every three weeks for 4 doses --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Treats side effects at 1/2 w/o w/holding</masterLabel>
            <translation><!-- Treats side effects at 1/2 w/o w/holding --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Withholds when 3/4 side effects presents</masterLabel>
            <translation><!-- Withholds when 3/4 side effects presents --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- How does the prescriber use Vectibix? --></label>
        <name>How_does_the_prescriber_use_Vectibix_BMS__c</name>
        <picklistValues>
            <masterLabel>Uses ERBITUX for combination but Vectibix as SA</masterLabel>
            <translation><!-- Uses ERBITUX for combination but Vectibix as SA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Uses Vectibix and ERBITUX equally</masterLabel>
            <translation><!-- Uses Vectibix and ERBITUX equally --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Uses Vectibix as SA late line following ERBITUX if at all</masterLabel>
            <translation><!-- Uses Vectibix as SA late line following ERBITUX if at all --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Uses Vectibix instead of ERBITUX in all settings</masterLabel>
            <translation><!-- Uses Vectibix instead of ERBITUX in all settings --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Please rate on a scale of 1-7 how important once daily dosing convenience with no fasting requirements is to customers when selecting a TKI for the treatment of CML? --></help>
        <label><!-- How important is once daily dosing? --></label>
        <name>How_important_is_once_daily_dosing_BMS__c</name>
        <picklistValues>
            <masterLabel>1 Not important at all</masterLabel>
            <translation><!-- 1 Not important at all --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>2 Relatively unimportant</masterLabel>
            <translation><!-- 2 Relatively unimportant --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>3 Slightly less important than other factors</masterLabel>
            <translation><!-- 3 Slightly less important than other factors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>4 Equal in importance to other factors</masterLabel>
            <translation><!-- 4 Equal in importance to other factors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5 Slightly more important than other factors</masterLabel>
            <translation><!-- 5 Slightly more important than other factors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>6 One of the top considerations</masterLabel>
            <translation><!-- 6 One of the top considerations --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>7 The most important consideration</masterLabel>
            <translation><!-- 7 The most important consideration --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- How many CML patients does this prescriber manage as the primery Oncologist/Hematologist?  Please include all CML patients, not just newly diagnosed ones. --></help>
        <label><!-- How many CML patients? --></label>
        <name>How_many_CML_patients_BMS__c</name>
        <picklistValues>
            <masterLabel>0</masterLabel>
            <translation><!-- 0 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>1</masterLabel>
            <translation><!-- 1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>10</masterLabel>
            <translation><!-- 10 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>11</masterLabel>
            <translation><!-- 11 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>12</masterLabel>
            <translation><!-- 12 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>13</masterLabel>
            <translation><!-- 13 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>14</masterLabel>
            <translation><!-- 14 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>15</masterLabel>
            <translation><!-- 15 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>16</masterLabel>
            <translation><!-- 16 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>17</masterLabel>
            <translation><!-- 17 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>18</masterLabel>
            <translation><!-- 18 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>19</masterLabel>
            <translation><!-- 19 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>2</masterLabel>
            <translation><!-- 2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>20</masterLabel>
            <translation><!-- 20 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>3</masterLabel>
            <translation><!-- 3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>4</masterLabel>
            <translation><!-- 4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5</masterLabel>
            <translation><!-- 5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>6</masterLabel>
            <translation><!-- 6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>7</masterLabel>
            <translation><!-- 7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>8</masterLabel>
            <translation><!-- 8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>9</masterLabel>
            <translation><!-- 9 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>&gt;20</masterLabel>
            <translation><!-- &gt;20 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- How many unique Ph+ ALL patients does this prescriber see per year? --></help>
        <label><!-- How many PH+ All patients / year? --></label>
        <name>How_many_PH_All_patients_year_BMS__c</name>
        <picklistValues>
            <masterLabel>0</masterLabel>
            <translation><!-- 0 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>1</masterLabel>
            <translation><!-- 1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>10</masterLabel>
            <translation><!-- 10 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>2</masterLabel>
            <translation><!-- 2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>3</masterLabel>
            <translation><!-- 3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>4</masterLabel>
            <translation><!-- 4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5</masterLabel>
            <translation><!-- 5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>6</masterLabel>
            <translation><!-- 6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>7</masterLabel>
            <translation><!-- 7 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>8</masterLabel>
            <translation><!-- 8 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>9</masterLabel>
            <translation><!-- 9 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>&gt;10</masterLabel>
            <translation><!-- &gt;10 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time, but will investigate</masterLabel>
            <translation><!-- Don&apos;t know at this time, but will investigate --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Nbr of Patients in practice MM (Stage IIIC and IV) in past 12 months? --></help>
        <label><!-- IIIC&amp;IV MM patients --></label>
        <name>IIIC_IV_MM_patients_BMS_CA__c</name>
    </fields>
    <fields>
        <help><!-- Are there any reimbursement concerns the practice may have regarding IXEMPRA? --></help>
        <label><!-- IXEMPRA reimbursement concerns? --></label>
        <name>IXEMPRA_reimbursement_concerns_BMS__c</name>
        <picklistValues>
            <masterLabel>Has had issues, concerns are limiting use</masterLabel>
            <translation><!-- Has had issues, concerns are limiting use --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Is not conferrable with how to bill or code for the IXEMBRA and seems to have many issues and questions which have not been resolved</masterLabel>
            <translation><!-- Is not conferrable with how to bill or code for the IXEMBRA and seems to have many issues and questions which have not been resolved --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reimbursement is not an issue and practice is comfortable with all of BMS support services</masterLabel>
            <translation><!-- Reimbursement is not an issue and practice is comfortable with all of BMS support services --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Sometime uses the IXEMPRA only where reimbursement will not be a concern</masterLabel>
            <translation><!-- Sometime uses the IXEMPRA only where reimbursement will not be a concern --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- In which line of therapy is IXEMPRA typically used as combo therapy with XELODA? --></help>
        <label><!-- IXEMPRA used as combo with XELODA? --></label>
        <name>IXEMPRA_used_as_combo_with_XELODA_BMS__c</name>
        <picklistValues>
            <masterLabel>1st or 2nd</masterLabel>
            <translation><!-- 1st or 2nd --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>3rd or 4th</masterLabel>
            <translation><!-- 3rd or 4th --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5th or later</masterLabel>
            <translation><!-- 5th or later --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Any line but only in specific subset</masterLabel>
            <translation><!-- Any line but only in specific subset --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Never used</masterLabel>
            <translation><!-- Never used --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- If no temp codes, how is it handled? --></label>
        <name>If_no_how_is_situation_handled_BMS__c</name>
        <picklistValues>
            <masterLabel>Choose other treatment options</masterLabel>
            <translation><!-- Choose other treatment options --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Send patient to hospital</masterLabel>
            <translation><!-- Send patient to hospital --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Send patient to non-hospital infusion center</masterLabel>
            <translation><!-- Send patient to non-hospital infusion center --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- If other, specify percentage --></label>
        <name>If_other_specify_percentage_BMS__c</name>
        <picklistValues>
            <masterLabel>0-10%</masterLabel>
            <translation><!-- 0-10% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>11-20%</masterLabel>
            <translation><!-- 11-20% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>21-30%</masterLabel>
            <translation><!-- 21-30% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>31-40%</masterLabel>
            <translation><!-- 31-40% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>41-50%</masterLabel>
            <translation><!-- 41-50% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>51-60%</masterLabel>
            <translation><!-- 51-60% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>61-70%</masterLabel>
            <translation><!-- 61-70% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>71-80%</masterLabel>
            <translation><!-- 71-80% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>81-90%</masterLabel>
            <translation><!-- 81-90% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>91-100%</masterLabel>
            <translation><!-- 91-100% --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Placed on YERVOY Since Lauch --></label>
        <name>Individual_Placed_on_YERVOY_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Seen Since YERVOY Launch --></label>
        <name>Individual_Seen_Since_YERVOY_Launch_BMS__c</name>
    </fields>
    <fields>
        <help><!-- How influential is this prescriber in the practice&apos;s therapy decisions? --></help>
        <label><!-- Inflntl in practice&apos;s thrpy decisions? --></label>
        <name>Inflntl_in_practices_thrpy_decisions_BMS__c</name>
        <picklistValues>
            <masterLabel>Not Influential</masterLabel>
            <translation><!-- Not Influential --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Somewhat influential</masterLabel>
            <translation><!-- Somewhat influential --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Very influential - practice leader</masterLabel>
            <translation><!-- Very influential - practice leader --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Is this prescriber influential in the treatment of CML? --></help>
        <label><!-- Influential in the treatment of CML? --></label>
        <name>Influential_in_the_treatment_of_CML_BMS__c</name>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes (Local Influencer)</masterLabel>
            <translation><!-- Yes (Local Influencer) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes (National Influencer)</masterLabel>
            <translation><!-- Yes (National Influencer) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes (Regional Influencer)</masterLabel>
            <translation><!-- Yes (Regional Influencer) --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Is this prescriber influential in the treatment of CRC? --></help>
        <label><!-- Influential in the treatment of CRC? --></label>
        <name>Influential_in_the_treatment_of_CRC_BMS__c</name>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes (Local Influencer)</masterLabel>
            <translation><!-- Yes (Local Influencer) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes (Regional Influencer)</masterLabel>
            <translation><!-- Yes (Regional Influencer) --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Is the prescriber influential in the treatment of metastatic Breast Cancer? --></help>
        <label><!-- Influential in trtmnt of Breast Cancer --></label>
        <name>Influential_in_trtmnt_Breast_Cancer_BMS__c</name>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes (local influencer)</masterLabel>
            <translation><!-- Yes (local influencer) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes (national influencer)</masterLabel>
            <translation><!-- Yes (national influencer) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes (within account)</masterLabel>
            <translation><!-- Yes (within account) --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- How influential is this prescriber outside the practice? --></help>
        <label><!-- Influential outside of the practice? --></label>
        <name>Influential_outside_of_the_practice_BMS__c</name>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Locally influential</masterLabel>
            <translation><!-- Locally influential --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nationally influential</masterLabel>
            <translation><!-- Nationally influential --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not influential</masterLabel>
            <translation><!-- Not influential --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regionally influential</masterLabel>
            <translation><!-- Regionally influential --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Is the prescriber influential in the treatment of SCCHN? --></help>
        <label><!-- Influential in the treatment of SCCHN? --></label>
        <name>Inluential_in_the_treatment_of_SCCHN_BMS__c</name>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not at this time</masterLabel>
            <translation><!-- Not at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes (national influencer)</masterLabel>
            <translation><!-- Yes (national influencer) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes (regional influencer)</masterLabel>
            <translation><!-- Yes (regional influencer) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes (within account)</masterLabel>
            <translation><!-- Yes (within account) --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- How frequently does this prescriber use Irinotecan in the first line of therapy? --></help>
        <label><!-- Irinotecan as first line of therapy? --></label>
        <name>Irinotecan_as_first_line_of_therapy_BMS__c</name>
        <picklistValues>
            <masterLabel>Almost Always</masterLabel>
            <translation><!-- Almost Always --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Almost Never</masterLabel>
            <translation><!-- Almost Never --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Frequently</masterLabel>
            <translation><!-- Frequently --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Infrequently</masterLabel>
            <translation><!-- Infrequently --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not Applicable</masterLabel>
            <translation><!-- Not Applicable --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Sometimes</masterLabel>
            <translation><!-- Sometimes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Is this HCP influential within? --></label>
        <name>Is_this_HCP_influential_within_BMS__c</name>
        <picklistValues>
            <masterLabel>Locally in their community</masterLabel>
            <translation><!-- Locally in their community --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nationally</masterLabel>
            <translation><!-- Nationally --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not at all</masterLabel>
            <translation><!-- Not at all --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Their own practice</masterLabel>
            <translation><!-- Their own practice --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>With their regional Colleagues</masterLabel>
            <translation><!-- With their regional Colleagues --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- HCP has knowledge necessary to manage adverse events associated with YERVOY? (Choose all that apply) --></help>
        <label><!-- Knowledge to manage adverse events? --></label>
        <name>Knowledge_to_manage_adverse_YEVOY_BMS__c</name>
        <picklistValues>
            <masterLabel>Based on experience with the Product</masterLabel>
            <translation><!-- Based on experience with the Product --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Based on involvement in Clinical trials</masterLabel>
            <translation><!-- Based on involvement in Clinical trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Based on review of the clinical info</masterLabel>
            <translation><!-- Based on review of the clinical info --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Needs more information</masterLabel>
            <translation><!-- Needs more information --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help>Hoe groot is de kans dat de KOL patiëntprofieldocumenten zal gebruiken?</help>
        <label>Patiëntprofielen LN</label>
        <name>LN_Patient_Profiles__c</name>
        <picklistValues>
            <masterLabel>Somewhat Likely</masterLabel>
            <translation>Enigszins waarschijnlijk</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unlikely</masterLabel>
            <translation>Onwaarschijnlijk</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Very Likely</masterLabel>
            <translation>Zeer waarschijnlijk</translation>
        </picklistValues>
    </fields>
    <fields>
        <help>Hoe groot is de kans dat de KOL onderzoeksresultaten voor Labrinone zal gebruiken in bezoeken met collega&apos;s?</help>
        <label>Onderzoekstoepassing LN</label>
        <name>LN_Study_Leverage__c</name>
        <picklistValues>
            <masterLabel>Somewhat Likely</masterLabel>
            <translation>Enigszins waarschijnlijk</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unlikely</masterLabel>
            <translation>Onwaarschijnlijk</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Very Likely</masterLabel>
            <translation>Zeer waarschijnlijk</translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- What percentage of the business (payer) mix in the office is Medicaid? --></help>
        <label><!-- Medicaid --></label>
        <name>Medicaid_BMS__c</name>
        <picklistValues>
            <masterLabel>0-10%</masterLabel>
            <translation><!-- 0-10% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>11-20%</masterLabel>
            <translation><!-- 11-20% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>21-30%</masterLabel>
            <translation><!-- 21-30% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>31-40%</masterLabel>
            <translation><!-- 31-40% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>41-50%</masterLabel>
            <translation><!-- 41-50% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>51-60%</masterLabel>
            <translation><!-- 51-60% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>61-70%</masterLabel>
            <translation><!-- 61-70% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>71-80%</masterLabel>
            <translation><!-- 71-80% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>81-90%</masterLabel>
            <translation><!-- 81-90% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>91-100%</masterLabel>
            <translation><!-- 91-100% --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- What percentage of the business (payer) mix in the office is Medicare? --></help>
        <label><!-- Medicare --></label>
        <name>Medicare_BMS__c</name>
        <picklistValues>
            <masterLabel>0-10%</masterLabel>
            <translation><!-- 0-10% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>11-20%</masterLabel>
            <translation><!-- 11-20% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>21-30%</masterLabel>
            <translation><!-- 21-30% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>31-40%</masterLabel>
            <translation><!-- 31-40% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>41-50%</masterLabel>
            <translation><!-- 41-50% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>51-60%</masterLabel>
            <translation><!-- 51-60% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>61-70%</masterLabel>
            <translation><!-- 61-70% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>71-80%</masterLabel>
            <translation><!-- 71-80% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>81-90%</masterLabel>
            <translation><!-- 81-90% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>91-100%</masterLabel>
            <translation><!-- 91-100% --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Number of new metastatic patients treated per year (either recurrent metastatic or newly diagnosed metastatic)? --></help>
        <label><!-- New metastatic patients per year? --></label>
        <name>Metastatic_patients_treated_per_year_BMS__c</name>
    </fields>
    <fields>
        <help><!-- How do you like to receive new product information? (check all that apply) --></help>
        <label><!-- Method to receive new product info --></label>
        <name>Method_to_recieve_new_product_info_BMS__c</name>
        <picklistValues>
            <masterLabel>CMEs</masterLabel>
            <translation><!-- CMEs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Dinner programs</masterLabel>
            <translation><!-- Dinner programs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Email</masterLabel>
            <translation><!-- Email --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Epocrates</masterLabel>
            <translation><!-- Epocrates --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Hard Copy</masterLabel>
            <translation><!-- Hard Copy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Journal</masterLabel>
            <translation><!-- Journal --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lunch programs</masterLabel>
            <translation><!-- Lunch programs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MSL</masterLabel>
            <translation><!-- MSL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Medical Meetings</masterLabel>
            <translation><!-- Medical Meetings --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Mobile device/Smart Phone</masterLabel>
            <translation><!-- Mobile device/Smart Phone --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Peer Dialogue</masterLabel>
            <translation><!-- Peer Dialogue --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Sales Rep</masterLabel>
            <translation><!-- Sales Rep --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Tumor Boards</masterLabel>
            <translation><!-- Tumor Boards --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Web</masterLabel>
            <translation><!-- Web --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>WebMD</masterLabel>
            <translation><!-- WebMD --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Webcasts</masterLabel>
            <translation><!-- Webcasts --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Mobile ID --></label>
        <name>Mobile_ID_vod__c</name>
    </fields>
    <fields>
        <help><!-- Which side effect, creates concerns that limits the HCP&apos;s use of YERVOY? (Choose all that apply) --></help>
        <label><!-- Most concerning YERVOY side effect? --></label>
        <name>Most_concerning_YERVOY_sideffect_BMS__c</name>
        <picklistValues>
            <masterLabel>Dermatologic Toxicity</masterLabel>
            <translation><!-- Dermatologic Toxicity --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Endocrine Toxicity</masterLabel>
            <translation><!-- Endocrine Toxicity --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GI Toxicity</masterLabel>
            <translation><!-- GI Toxicity --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Hepatic Toxicity</masterLabel>
            <translation><!-- Hepatic Toxicity --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Neurological Toxicity</masterLabel>
            <translation><!-- Neurological Toxicity --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>None</masterLabel>
            <translation><!-- None --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other Toxicity</masterLabel>
            <translation><!-- Other Toxicity --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- How useful does the customer consider the &quot;My Sprycel&quot; Patient Support Program to be? --></help>
        <label><!-- &quot;My Sprycel&quot; Patient Support Program --></label>
        <name>My_Sprycel_Patient_Support_Program_BMS__c</name>
        <picklistValues>
            <masterLabel>Aware of the programs, but don&apos;t see the value in them</masterLabel>
            <translation><!-- Aware of the programs, but don&apos;t see the value in them --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Find the support programs useful and makes regular use of them</masterLabel>
            <translation><!-- Find the support programs useful and makes regular use of them --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Find the support programs useful, but make limited use of them</masterLabel>
            <translation><!-- Find the support programs useful, but make limited use of them --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not aware of &quot;My Sprycel&quot; Patient Support Programs</masterLabel>
            <translation><!-- Not aware of &quot;My Sprycel&quot; Patient Support Programs --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- What are the 3 most important factors when selecting anticoagulant options for your AFib patients? --></help>
        <label><!-- Top 3 Factors - Anticoagulant --></label>
        <name>Office_Based_Learning_Q1_BMS__c</name>
        <picklistValues>
            <masterLabel>Bleeding</masterLabel>
            <translation><!-- Bleeding --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Co-pays/cost to patients</masterLabel>
            <translation><!-- Co-pays/cost to patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Dosing</masterLabel>
            <translation><!-- Dosing --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy</masterLabel>
            <translation><!-- Efficacy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Managed care coverage</masterLabel>
            <translation><!-- Managed care coverage --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other side effects</masterLabel>
            <translation><!-- Other side effects --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- What are the top three barriers for prescribing an anticoagulant other than Warfarin for your AFIB patients? (Select all that apply) --></help>
        <label><!-- Top 3 Barriers Prescribing Anticoagulant --></label>
        <name>Office_Based_Learning_Q2_BMS__c</name>
        <picklistValues>
            <masterLabel>Co-pays/cost to patient</masterLabel>
            <translation><!-- Co-pays/cost to patient --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Inability to monitor = disadvantage</masterLabel>
            <translation><!-- Inability to monitor = disadvantage --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Managed care coverage</masterLabel>
            <translation><!-- Managed care coverage --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not convinced by data</masterLabel>
            <translation><!-- Not convinced by data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prefer to wait</masterLabel>
            <translation><!-- Prefer to wait --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Resistance to changing therapy</masterLabel>
            <translation><!-- Resistance to changing therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Side effects</masterLabel>
            <translation><!-- Side effects --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Have you prescribed and anticoagulant other than Warfrin for any other AFib patients? --></help>
        <label><!-- Other anticoagulants prescribed --></label>
        <name>Office_Based_Learning_Q3_BMS__c</name>
        <picklistValues>
            <masterLabel>No (If answered NO, then skip to question 5)</masterLabel>
            <translation><!-- No (If answered NO, then skip to question 5) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help>Is deze arts lid van de lokale Oncology Board?</help>
        <label>Oncology Board</label>
        <name>Oncology_Board__c</name>
    </fields>
    <fields>
        <help><!-- How many unresectable or metastatic melanoma patients have the practice placed since YERVOY launch? --></help>
        <label><!-- Placed on YERVOY Since Launch --></label>
        <name>Organization_Placed_on_YERVOY_BMS__c</name>
    </fields>
    <fields>
        <help><!-- How many unresectable or metastatic melanoma patients have the practice seen since YERVOY launch? --></help>
        <label><!-- Seen Since YERVOY Launch --></label>
        <name>Organization_Seen_Since_YERVOY_BMS__c</name>
    </fields>
    <fields>
        <help><!-- What percentage of the business (payer) mix in the office is from other? --></help>
        <label><!-- Other Business (Payer) --></label>
        <name>Other_Business_Payer_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Other First --></label>
        <name>Other_First_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Other Review Times --></label>
        <name>Other_Review_Times_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Other Second --></label>
        <name>Other_Second__c</name>
    </fields>
    <fields>
        <label><!-- Other Suppliers --></label>
        <name>Other_Suppliers_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Other Third --></label>
        <name>Other_Third_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Other method to receive new product info --></label>
        <name>Other_method_to_receive_new_product_info__c</name>
    </fields>
    <fields>
        <help><!-- Does this practice/hospital implement their own medical policy/formulary that may impact product access beyond the policies set by a health plan? --></help>
        <label><!-- Own medical policy / formulary? --></label>
        <name>Own_medical_policy_formulary_BMS__c</name>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- How many patient kits have been placed in this practice? --></help>
        <label><!-- Patient Kits Placed --></label>
        <name>Patient_Kits_Placed_BMS__c</name>
    </fields>
    <fields>
        <help><!-- In the last 6 months, for which AFib patient types have you prescribed an anticoagulant other than Warfrin --></help>
        <label><!-- AFib patient types --></label>
        <name>Patient_types__c</name>
        <picklistValues>
            <masterLabel>Difficult to control</masterLabel>
            <translation><!-- Difficult to control --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Newly diagnosed</masterLabel>
            <translation><!-- Newly diagnosed --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>None</masterLabel>
            <translation><!-- None --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Patient choice</masterLabel>
            <translation><!-- Patient choice --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Previously diagnosed, but untreated</masterLabel>
            <translation><!-- Previously diagnosed, but untreated --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Does the prescriber treat patients with metastatic Breast Cancer? --></help>
        <label><!-- Patients with metastatic Breast Cancer? --></label>
        <name>Patients_metastatic_Breast_Cancer_BMS__c</name>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Approximately how many patients has the prescriber treated with IXEMPRA in the last 6 months? --></help>
        <label><!-- Patients treated with IXEMPRA --></label>
        <name>Patients_treated_with_IXEMPRA_BMS__c</name>
        <picklistValues>
            <masterLabel>0</masterLabel>
            <translation><!-- 0 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>1-3</masterLabel>
            <translation><!-- 1-3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>4-9</masterLabel>
            <translation><!-- 4-9 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Do they plan to use 2nd generation TKIs in 1st Line or save them for 2nd Line? --></help>
        <label><!-- Plan to use 2nd Gen TKIs in 1st Line? --></label>
        <name>Plan_to_use_2nd_Gen_TKIs_in_1st_Line_BMS__c</name>
        <picklistValues>
            <masterLabel>Use in 1st Line</masterLabel>
            <translation><!-- Use in 1st Line --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Use in 2nd Line - save them for 2nd, don&apos;t want to run out of options</masterLabel>
            <translation><!-- Use in 2nd Line - save them for 2nd, don&apos;t want to run out of options --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Is this HCP a positive or negative advocate for YERVOY? --></help>
        <label><!-- Positive or Negative YERVOY advocate? --></label>
        <name>Positive_or_Negative_YERVOY_advocate_BMS__c</name>
        <picklistValues>
            <masterLabel>Negative</masterLabel>
            <translation><!-- Negative --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nuetral</masterLabel>
            <translation><!-- Nuetral --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Positive</masterLabel>
            <translation><!-- Positive --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Very Negative</masterLabel>
            <translation><!-- Very Negative --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Very Positive</masterLabel>
            <translation><!-- Very Positive --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Rate the prescribers potential for use of SPRYCEL. --></help>
        <label><!-- Potential for use of SPRYCEL --></label>
        <name>Potential_for_use_of_SPRYCEL_BMS__c</name>
        <picklistValues>
            <masterLabel>Average</masterLabel>
            <translation><!-- Average --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>High</masterLabel>
            <translation><!-- High --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Low (Do not include in call plan)</masterLabel>
            <translation><!-- Low (Do not include in call plan) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Low but with potential to use</masterLabel>
            <translation><!-- Low but with potential to use --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lower than average</masterLabel>
            <translation><!-- Lower than average --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Very high</masterLabel>
            <translation><!-- Very high --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Rate the prescriber&apos;s potential for use of ERBITUX (CRC) --></help>
        <label><!-- Potential use of ERBITUX (CRC) --></label>
        <name>Potential_use_of_ERBITUX_CRC_BMS__c</name>
        <picklistValues>
            <masterLabel>Average</masterLabel>
            <translation><!-- Average --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>High</masterLabel>
            <translation><!-- High --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Low (do not include in call plan)</masterLabel>
            <translation><!-- Low (do not include in call plan) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lower but with potential to use</masterLabel>
            <translation><!-- Lower but with potential to use --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lower than average</masterLabel>
            <translation><!-- Lower than average --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Very High</masterLabel>
            <translation><!-- Very High --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Rate the prescriber&apos;s potential for use of ERBITUX in appropriate SCCHN patients. --></help>
        <label><!-- Potential use of ERBITUX in SCCHN ptnts? --></label>
        <name>Potential_use_of_ERBITUX_in_SCCHN_BMS__c</name>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>High</masterLabel>
            <translation><!-- High --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Low (do to include in Call Plan)</masterLabel>
            <translation><!-- Low (do to include in Call Plan) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Low/None</masterLabel>
            <translation><!-- Low/None --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Moderate</masterLabel>
            <translation><!-- Moderate --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Very High</masterLabel>
            <translation><!-- Very High --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Rate the prescriber&apos;s potential for use of IXEMPRA. --></help>
        <label><!-- Potential use of IXEMPRA? --></label>
        <name>Potential_use_of_IXEMPRA_BMS__c</name>
        <picklistValues>
            <masterLabel>Average</masterLabel>
            <translation><!-- Average --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>High</masterLabel>
            <translation><!-- High --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Low (do not include in call plan)</masterLabel>
            <translation><!-- Low (do not include in call plan) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Low but with potential to use</masterLabel>
            <translation><!-- Low but with potential to use --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lower than average</masterLabel>
            <translation><!-- Lower than average --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Very high</masterLabel>
            <translation><!-- Very high --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- How likely would MD send a MM patient for Tx at PRIVATE infusion clinic?
(Definitely, Definitely not, Might-Might Not, Probably, Probably Not) --></help>
        <label><!-- Pr to use PRIVATE inf clinic --></label>
        <name>Pr_to_use_PRIVATE_inf_clinic_BMS_CA__c</name>
    </fields>
    <fields>
        <help><!-- Can a product be used prior to formulary review/inclusion? --></help>
        <label><!-- Prdct used prior to formulary rev/incl? --></label>
        <name>Prdct_used_prior_to_formulary_BMS__c</name>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not applicable</masterLabel>
            <translation><!-- Not applicable --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes (if a product meets unmet medical needs)</masterLabel>
            <translation><!-- Yes (if a product meets unmet medical needs) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes (with paperwork)</masterLabel>
            <translation><!-- Yes (with paperwork) --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help>Geef de naam op van de favoriete patholoog van de arts</help>
        <label>Favoriete patholoog</label>
        <name>Preferred_Pathologist__c</name>
    </fields>
    <fields>
        <help><!-- What is the prescriber&apos;s preferred treatment approach? --></help>
        <label><!-- Prescriber&apos;s preferred trtmnt approach? --></label>
        <name>Prescibers_preferred_trtmnt_approach_BMS__c</name>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Immediate use of combination therapy</masterLabel>
            <translation><!-- Immediate use of combination therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Progression of mono and combo therapies</masterLabel>
            <translation><!-- Progression of mono and combo therapies --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Sequential monotherapies</masterLabel>
            <translation><!-- Sequential monotherapies --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Split based on patient type</masterLabel>
            <translation><!-- Split based on patient type --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Does your office prescribe products with temporary codes? --></help>
        <label><!-- Prescribe products with temporary codes? --></label>
        <name>Prescribe_products_temporary_codes_BMS__c</name>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not applicable</masterLabel>
            <translation><!-- Not applicable --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q10. Approved Sprycel --></label>
        <name>Q10_Approved_Sprycel_BMS_US__c</name>
    </fields>
    <fields>
        <label><!-- Q10. Comments --></label>
        <name>Q10_Comments_Form_Flas_US__c</name>
    </fields>
    <fields>
        <label><!-- Q10. Comments --></label>
        <name>Q10_Comments__c</name>
    </fields>
    <fields>
        <help><!-- Comments for Q10 --></help>
        <label><!-- Q10. Comments --></label>
        <name>Q10_Comments_generic__c</name>
    </fields>
    <fields>
        <label><!-- Q10. Eliquis --></label>
        <name>Q10_Eliquis_Form_Flash_BMS_US__c</name>
    </fields>
    <fields>
        <help><!-- Please enter the competitive Formulary Status or Medical Policy --></help>
        <label><!-- Q10. Formulary Flash --></label>
        <name>Q10_Formulary_Flash_BMS_US__c</name>
        <picklistValues>
            <masterLabel>No Medical Policy, PA</masterLabel>
            <translation><!-- No Medical Policy, PA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No Medical Policy, no PA</masterLabel>
            <translation><!-- No Medical Policy, no PA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Non-PDL</masterLabel>
            <translation><!-- Non-PDL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nopolicyconsist w/labelpendP&amp;T</masterLabel>
            <translation><!-- Nopolicyconsist w/labelpendP&amp;T --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not Covered</masterLabel>
            <translation><!-- Not Covered --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other (see comments)</masterLabel>
            <translation><!-- Other (see comments) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PDL</masterLabel>
            <translation><!-- PDL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Policy consistent w/label noPA</masterLabel>
            <translation><!-- Policy consistent w/label noPA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Policy consistent w/label, PA</masterLabel>
            <translation><!-- Policy consistent w/label, PA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Policy more restrictive, PA</masterLabel>
            <translation><!-- Policy more restrictive, PA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Policy more restrictive, no PA</masterLabel>
            <translation><!-- Policy more restrictive, no PA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T1 Generic</masterLabel>
            <translation><!-- T1 Generic --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T1 Preferred Generic</masterLabel>
            <translation><!-- T1 Preferred Generic --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T2 Non-preferred Generic</masterLabel>
            <translation><!-- T2 Non-preferred Generic --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T2 Preferred Brand</masterLabel>
            <translation><!-- T2 Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T3 Non-preferred Brand</masterLabel>
            <translation><!-- T3 Non-preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T3 Preferred Brand</masterLabel>
            <translation><!-- T3 Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T4 Non-preferred brand</masterLabel>
            <translation><!-- T4 Non-preferred brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T4 Specialty Tier</masterLabel>
            <translation><!-- T4 Specialty Tier --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T5 Specialty Tier</masterLabel>
            <translation><!-- T5 Specialty Tier --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Please enter whether the plan recognizes Orencia SC as a unique MOA alternative to non anti-TNF therapy? --></help>
        <label><!-- Q10. Orencia Profiling --></label>
        <name>Q10_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Maybe</masterLabel>
            <translation><!-- Maybe --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Comments for Q11. --></help>
        <label><!-- Q11. Comments --></label>
        <name>Q11_Comments_generic__c</name>
    </fields>
    <fields>
        <label><!-- Q11. Formulary Flash --></label>
        <name>Q11_Formulary_Flash_BMS_US__c</name>
    </fields>
    <fields>
        <help><!-- Please record whether the plan would consider creating a separate category for Orencia SC within the next year? --></help>
        <label><!-- Q11. Orencia Profiling --></label>
        <name>Q11_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Maybe</masterLabel>
            <translation><!-- Maybe --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No, please explain in comments</masterLabel>
            <translation><!-- No, please explain in comments --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Comments for Q12. --></help>
        <label><!-- Q12. Comments --></label>
        <name>Q12_Comments_generic__c</name>
    </fields>
    <fields>
        <label><!-- Q12. Formulary Flash --></label>
        <name>Q12_Formulary_Flash_BMS_US__c</name>
    </fields>
    <fields>
        <help><!-- Please record whether the plan is satisfied with their current RA category management --></help>
        <label><!-- Q12. Orencia Profiling --></label>
        <name>Q12_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Maybe</masterLabel>
            <translation><!-- Maybe --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Comments for Q13. --></help>
        <label><!-- Q13. Comments --></label>
        <name>Q13_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- Please record whether initial Coverage of SC change after full class review (P&amp;T)? --></help>
        <label><!-- Q13. Orencia Profiling --></label>
        <name>Q13_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Maybe</masterLabel>
            <translation><!-- Maybe --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Comments for Q14. --></help>
        <label><!-- Q14. Comments --></label>
        <name>Q14_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- Please record whether P&amp;T review be required for initial reimbursement? --></help>
        <label><!-- Q14. Orencia Profiling --></label>
        <name>Q14_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Maybe</masterLabel>
            <translation><!-- Maybe --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Comments for Q15. --></help>
        <label><!-- Q15. Comments --></label>
        <name>Q15_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- Please record whether the plan is receptive to contracting to add Orencia SC to a preferred tier? --></help>
        <label><!-- Q15. Orencia Profile --></label>
        <name>Q15_Orencia_Profile_BMS__c</name>
        <picklistValues>
            <masterLabel>Maybe</masterLabel>
            <translation><!-- Maybe --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Comments for Q16. --></help>
        <label><!-- Q16. Comments --></label>
        <name>Q16_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- Please record whether this is the anticipated position for Orencia SC If all products have equal tier status. --></help>
        <label><!-- Q16. Orencia Profiling --></label>
        <name>Q16_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Maybe</masterLabel>
            <translation><!-- Maybe --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Comments for Q17. --></help>
        <label><!-- Q17. Comments --></label>
        <name>Q17_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- Please enter what opportunities exist to remain equal tier status to the other SC agents --></help>
        <label><!-- Q17. Orencia Profiling --></label>
        <name>Q17_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Access Rebate Levels</masterLabel>
            <translation><!-- Access Rebate Levels --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>All at parity</masterLabel>
            <translation><!-- All at parity --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other (enter in comments)</masterLabel>
            <translation><!-- Other (enter in comments) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Separate class for ORENCIA</masterLabel>
            <translation><!-- Separate class for ORENCIA --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Comments for Q18. --></help>
        <label><!-- Q18. Comments --></label>
        <name>Q18_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- Please record whether the plan will implement a more restrictive product offering? --></help>
        <label><!-- Q18. Orencia Profiling --></label>
        <name>Q18_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Maybe</masterLabel>
            <translation><!-- Maybe --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other (enter in comments)</masterLabel>
            <translation><!-- Other (enter in comments) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Comments for Q19. --></help>
        <label><!-- Q19. Comments --></label>
        <name>Q19_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- If yes, what is the timing to implement? --></help>
        <label><!-- Q19. Orencia Profiling --></label>
        <name>Q19_Orencia_Profiling_BMS_US__c</name>
    </fields>
    <fields>
        <label><!-- Q1. Approved Sprycel --></label>
        <name>Q1_Approved_Sprycel_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Gleevec parity, Tasigna higher</masterLabel>
            <translation><!-- Gleevec parity, Tasigna higher --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Higher than Gleevec or Tasigna</masterLabel>
            <translation><!-- Higher than Gleevec or Tasigna --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other, please comment</masterLabel>
            <translation><!-- Other, please comment --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Parity to Gleevec or Tasigna</masterLabel>
            <translation><!-- Parity to Gleevec or Tasigna --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SE through Gleevec</masterLabel>
            <translation><!-- SE through Gleevec --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SE through Gleevec and Tasigna</masterLabel>
            <translation><!-- SE through Gleevec and Tasigna --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Comments for Q1. What is your institution’s protocol for 1st line treatment of mCRC? --></help>
        <label><!-- Q1. Comments --></label>
        <name>Q1_Comments__c</name>
    </fields>
    <fields>
        <help><!-- Comments for Q1. --></help>
        <label><!-- Q1. Comments --></label>
        <name>Q1_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- Please enter when the P&amp;T Committee of this customer will most likely review Eliquis --></help>
        <label><!-- Q1. Eliquis Assess --></label>
        <name>Q1_Eliquis_Assess_BMS_US__c</name>
    </fields>
    <fields>
        <label><!-- Q1. Eliquis --></label>
        <name>Q1_Eliquis_BMS_US__c</name>
    </fields>
    <fields>
        <label><!-- Q1. Formulary Flash --></label>
        <name>Q1_Formulary_Flash_BMS_US__c</name>
        <picklistValues>
            <masterLabel>ABILIFY</masterLabel>
            <translation><!-- ABILIFY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ATRIPLA</masterLabel>
            <translation><!-- ATRIPLA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVALIDE</masterLabel>
            <translation><!-- AVALIDE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVAPRO</masterLabel>
            <translation><!-- AVAPRO --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVAPRO/AVALIDE</masterLabel>
            <translation><!-- AVAPRO/AVALIDE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BARACLUDE</masterLabel>
            <translation><!-- BARACLUDE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BYDUREON</masterLabel>
            <translation><!-- BYDUREON --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BYETTA</masterLabel>
            <translation><!-- BYETTA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ERBITUX</masterLabel>
            <translation><!-- ERBITUX --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IXEMPRA</masterLabel>
            <translation><!-- IXEMPRA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>KOMBIGLYZE XR</masterLabel>
            <translation><!-- KOMBIGLYZE XR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX</masterLabel>
            <translation><!-- NULOJIX --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONGLYZA</masterLabel>
            <translation><!-- ONGLYZA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONGLYZA FAMILY</masterLabel>
            <translation><!-- ONGLYZA FAMILY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ORENCIA</masterLabel>
            <translation><!-- ORENCIA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ORENCIA SC</masterLabel>
            <translation><!-- ORENCIA SC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PLAVIX</masterLabel>
            <translation><!-- PLAVIX --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>REYATAZ</masterLabel>
            <translation><!-- REYATAZ --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>REYTAZ</masterLabel>
            <translation><!-- REYTAZ --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL</masterLabel>
            <translation><!-- SPRYCEL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SUSTIVA</masterLabel>
            <translation><!-- SUSTIVA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SYMLIN</masterLabel>
            <translation><!-- SYMLIN --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY</masterLabel>
            <translation><!-- YERVOY --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q1. Orencia Profiling --></label>
        <name>Q1_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Contract for parity</masterLabel>
            <translation><!-- Contract for parity --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Contract for preferred</masterLabel>
            <translation><!-- Contract for preferred --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Contract for separate class</masterLabel>
            <translation><!-- Contract for separate class --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Contract to remove step edit/s</masterLabel>
            <translation><!-- Contract to remove step edit/s --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other (enter in comments)</masterLabel>
            <translation><!-- Other (enter in comments) --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Comments for Q20. --></help>
        <label><!-- Q20. Comments --></label>
        <name>Q20_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- Please record whether step therapy requirements are anticipated for Orencia SC? --></help>
        <label><!-- Q20. Orencia Profiling --></label>
        <name>Q20_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Maybe</masterLabel>
            <translation><!-- Maybe --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other (enter in comments)</masterLabel>
            <translation><!-- Other (enter in comments) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Comments for Q21. --></help>
        <label><!-- Q21. Comments --></label>
        <name>Q21_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- If yes, please record whether benefit designs/competitive contracting would allow no step edits for Orencia SC. --></help>
        <label><!-- Q21. Orencia Profiling --></label>
        <name>Q21_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Maybe</masterLabel>
            <translation><!-- Maybe --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Comments for Q22. --></help>
        <label><!-- Q22. Comments --></label>
        <name>Q22_Comments_generic__c</name>
    </fields>
    <fields>
        <label><!-- Q22. Orencia Profiling --></label>
        <name>Q22_Orencia_Profiling_BMS_US__c</name>
    </fields>
    <fields>
        <help><!-- Comments Q23. --></help>
        <label><!-- Q23. Comments --></label>
        <name>Q23_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- Please record whether the formulary management is different between these two --></help>
        <label><!-- Q23. Orencia Profiling --></label>
        <name>Q23_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Maybe</masterLabel>
            <translation><!-- Maybe --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Comments for Q24. --></help>
        <label><!-- Q24. Comments --></label>
        <name>Q24_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- Please record whether there any anticipated changes in the formulary or reimbursement of ORENCIA IV. --></help>
        <label><!-- Q24. Orencia Profiling --></label>
        <name>Q24_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Maybe</masterLabel>
            <translation><!-- Maybe --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q2. Approved Sprycel --></label>
        <name>Q2_Approved_Sprycel_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Evidence in CML</masterLabel>
            <translation><!-- Evidence in CML --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No evidence for Specialty TA</masterLabel>
            <translation><!-- No evidence for Specialty TA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not sure</masterLabel>
            <translation><!-- Not sure --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other Specialty TA (e.g. RCC)</masterLabel>
            <translation><!-- Other Specialty TA (e.g. RCC) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other, please comment</masterLabel>
            <translation><!-- Other, please comment --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Comments for Q2. Is there a protocol for biomarker testing in patients with mCRC at your institution? If not, is there a prevailing practice as to when it occurs? --></help>
        <label><!-- Q2. Comments --></label>
        <name>Q2_Comments__c</name>
    </fields>
    <fields>
        <help><!-- Comments for Q2. --></help>
        <label><!-- Q2. Comments --></label>
        <name>Q2_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- Please enter the typical timeframe for gaining official formulary status after P&amp;T at this customer? --></help>
        <label><!-- Q2. Eliquis Assess --></label>
        <name>Q2_Eliquis_Assess_BMS_US__c</name>
        <picklistValues>
            <masterLabel>31-60 days post-P&amp;T</masterLabel>
            <translation><!-- 31-60 days post-P&amp;T --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>61-90 days post-P&amp;T</masterLabel>
            <translation><!-- 61-90 days post-P&amp;T --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>&gt; 90 days post-P&amp;T</masterLabel>
            <translation><!-- &gt; 90 days post-P&amp;T --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Immediate formulary change</masterLabel>
            <translation><!-- Immediate formulary change --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unsure/Don&apos;t Know</masterLabel>
            <translation><!-- Unsure/Don&apos;t Know --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Within 30 days of P&amp;T</masterLabel>
            <translation><!-- Within 30 days of P&amp;T --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q2. Eliquis --></label>
        <name>Q2_Eliquis_BMS_US__c</name>
    </fields>
    <fields>
        <label><!-- Q2. Formulary Flash --></label>
        <name>Q2_Formulary_Flash_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Commercial Only</masterLabel>
            <translation><!-- Commercial Only --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Commercial and MMA</masterLabel>
            <translation><!-- Commercial and MMA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Hospital/Specialty GPO</masterLabel>
            <translation><!-- Hospital/Specialty GPO --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MMA only</masterLabel>
            <translation><!-- MMA only --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Managed Medicaid</masterLabel>
            <translation><!-- Managed Medicaid --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Medicare Part B Carrier</masterLabel>
            <translation><!-- Medicare Part B Carrier --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PBM</masterLabel>
            <translation><!-- PBM --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Specialty Pharmacy</masterLabel>
            <translation><!-- Specialty Pharmacy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>State Medicaid</masterLabel>
            <translation><!-- State Medicaid --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VA/DOD</masterLabel>
            <translation><!-- VA/DOD --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q2. Orencia Profiling --></label>
        <name>Q2_Orencia_Profiling_BMS_US__c</name>
    </fields>
    <fields>
        <label><!-- Q3. Approved Sprycel --></label>
        <name>Q3_Approved_Sprycel_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Account and field confirmed</masterLabel>
            <translation><!-- Account and field confirmed --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Account reported only</masterLabel>
            <translation><!-- Account reported only --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No activity report</masterLabel>
            <translation><!-- No activity report --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other, please comment</masterLabel>
            <translation><!-- Other, please comment --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Stated/written policy</masterLabel>
            <translation><!-- Stated/written policy --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q3. Comments --></label>
        <name>Q3_Comments__c</name>
    </fields>
    <fields>
        <help><!-- Comments for Q3. --></help>
        <label><!-- Q3. Comments --></label>
        <name>Q3_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- Please enter what will likely be the default access for Eliquis at this customer prior to the P&amp;T review --></help>
        <label><!-- Q3. Eliquis Assess --></label>
        <name>Q3_Eliquis_Assess_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Not Covered</masterLabel>
            <translation><!-- Not Covered --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not Covered- Avail. by Appeal</masterLabel>
            <translation><!-- Not Covered- Avail. by Appeal --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other (please specify)</masterLabel>
            <translation><!-- Other (please specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T2 Non-Preferred Brand</masterLabel>
            <translation><!-- T2 Non-Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T2 Preferred Brand</masterLabel>
            <translation><!-- T2 Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T3 Non-Preferred Brand</masterLabel>
            <translation><!-- T3 Non-Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T3 Preferred Brand</masterLabel>
            <translation><!-- T3 Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T4 Non-Preferred Brand</masterLabel>
            <translation><!-- T4 Non-Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T4 Preferred Brand</masterLabel>
            <translation><!-- T4 Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unsure/Don&apos;t Know</masterLabel>
            <translation><!-- Unsure/Don&apos;t Know --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q3. Eliquis --></label>
        <name>Q3_Eliquis_BMS_US__c</name>
    </fields>
    <fields>
        <label><!-- Q3. Formulary Flash --></label>
        <name>Q3_Formulary_Flash_BMS_US__c</name>
    </fields>
    <fields>
        <help><!-- Please enter who the DBM matrix partners for this account are --></help>
        <label><!-- Q3. Orencia Profiling --></label>
        <name>Q3_Orencia_Profiling_BMS_US__c</name>
    </fields>
    <fields>
        <label><!-- Q4. Approved Sprycel --></label>
        <name>Q4_Approved_Sprycel_BMS_US__c</name>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No, working on it</masterLabel>
            <translation><!-- No, working on it --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes, planned</masterLabel>
            <translation><!-- Yes, planned --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q4. Comments --></label>
        <name>Q4_Comments__c</name>
    </fields>
    <fields>
        <help><!-- Comments for Q4. --></help>
        <label><!-- Q4. Comments --></label>
        <name>Q4_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- Please record the default management for Eliquis at this customer prior to the P&amp;T review --></help>
        <label><!-- Q4. Eliquis Assess --></label>
        <name>Q4_Eliquis_Assess_BMS_US__c</name>
        <picklistValues>
            <masterLabel>No Restrictions Anticipated</masterLabel>
            <translation><!-- No Restrictions Anticipated --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other (please specify)</masterLabel>
            <translation><!-- Other (please specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PA plus Step Edit</masterLabel>
            <translation><!-- PA plus Step Edit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prior Authorization (PA)</masterLabel>
            <translation><!-- Prior Authorization (PA) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Step Edit</masterLabel>
            <translation><!-- Step Edit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unsure/Don&apos;t Know</masterLabel>
            <translation><!-- Unsure/Don&apos;t Know --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q4. Eliquis --></label>
        <name>Q4_Eliquis_BMS_US__c</name>
    </fields>
    <fields>
        <label><!-- Q4. Formulary Flash --></label>
        <name>Q4_Formulary_Flash_BMS_US__c</name>
    </fields>
    <fields>
        <help><!-- Please enter whether the plan manages the RA formulary or if it relies on a PBM and if so, which one? --></help>
        <label><!-- Q4. Orencia Profiling --></label>
        <name>Q4_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q5. Approved Sprycel --></label>
        <name>Q5_Approved_Sprycel_BMS_US__c</name>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not sure CML no for other Tas</masterLabel>
            <translation><!-- Not sure CML no for other Tas --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not sure CML yes for other Tas</masterLabel>
            <translation><!-- Not sure CML yes for other Tas --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other, please comment</masterLabel>
            <translation><!-- Other, please comment --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q5. Comments --></label>
        <name>Q5_Comments__c</name>
    </fields>
    <fields>
        <help><!-- Comment for Q5. --></help>
        <label><!-- Q5. Comments --></label>
        <name>Q5_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- Please record whether Eliquis will be disadvantaged to Pradaxa and/or Xarelto in default access/management --></help>
        <label><!-- Q5. Eliquis Assess --></label>
        <name>Q5_Eliquis_Assess_BMS_US__c</name>
        <picklistValues>
            <masterLabel>No, will have parity access</masterLabel>
            <translation><!-- No, will have parity access --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unsure/Don&apos;t Know</masterLabel>
            <translation><!-- Unsure/Don&apos;t Know --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes, disadvantaged to Pradaxa</masterLabel>
            <translation><!-- Yes, disadvantaged to Pradaxa --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes, disadvantaged to Xarelto</masterLabel>
            <translation><!-- Yes, disadvantaged to Xarelto --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes, disadvantaged to both</masterLabel>
            <translation><!-- Yes, disadvantaged to both --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q5. Eliquis --></label>
        <name>Q5_Eliquis_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Gain</masterLabel>
            <translation><!-- Gain --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Loss</masterLabel>
            <translation><!-- Loss --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Maintain</masterLabel>
            <translation><!-- Maintain --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Maintain w/Competitor Change</masterLabel>
            <translation><!-- Maintain w/Competitor Change --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>New Product Default Coverage</masterLabel>
            <translation><!-- New Product Default Coverage --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q5. Formulary Flash --></label>
        <name>Q5_Formulary_Flash_BMS_US__c</name>
    </fields>
    <fields>
        <help><!-- Please enter whether the plan has a preferred specialty pharmacy they partner with for RA? If so, which one? --></help>
        <label><!-- Q5. Orencia Profiling --></label>
        <name>Q5_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q6. Approved Sprycel --></label>
        <name>Q6_Approved_Sprycel_BMS_US__c</name>
    </fields>
    <fields>
        <label><!-- Q6. Comments --></label>
        <name>Q6_Comments__c</name>
    </fields>
    <fields>
        <help><!-- Comments for Q6. --></help>
        <label><!-- Q6. Comments --></label>
        <name>Q6_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- Please record if the status will be published or communicated to HCPs if the customer covers Eliquis prior to P&amp;T --></help>
        <label><!-- Q6. Eliquis Assess --></label>
        <name>Q6_Eliquis_Assess_BMS_US__c</name>
        <picklistValues>
            <masterLabel>No,only thru HCP query/claim</masterLabel>
            <translation><!-- No,only thru HCP query/claim --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unsure/Don&apos;t Know</masterLabel>
            <translation><!-- Unsure/Don&apos;t Know --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes, published on formulary</masterLabel>
            <translation><!-- Yes, published on formulary --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q6. Eliquis --></label>
        <name>Q6_Eliquis_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Non-prescription drug list (PDL)</masterLabel>
            <translation><!-- Non-prescription drug list (PDL) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not Covered</masterLabel>
            <translation><!-- Not Covered --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not Covered - Avail. by Appeal</masterLabel>
            <translation><!-- Not Covered - Avail. by Appeal --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>On prescritpion drug list (PDL)</masterLabel>
            <translation><!-- On prescritpion drug list (PDL) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other (please specify)</masterLabel>
            <translation><!-- Other (please specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T2 Preferred Brand</masterLabel>
            <translation><!-- T2 Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T3 Non-Preferred Brand</masterLabel>
            <translation><!-- T3 Non-Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T3 Preferred Brand</masterLabel>
            <translation><!-- T3 Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T4 Non-Preferred Brand</masterLabel>
            <translation><!-- T4 Non-Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unsure/Don&apos;t Know</masterLabel>
            <translation><!-- Unsure/Don&apos;t Know --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q6. Eliquis --></label>
        <name>Q6_Eliquis_Form_Flash_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Non-prescription drug list (PDL)</masterLabel>
            <translation><!-- Non-prescription drug list (PDL) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Non-prescription drug list(non-PDL)</masterLabel>
            <translation><!-- Non-prescription drug list(non-PDL) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not Covered</masterLabel>
            <translation><!-- Not Covered --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not Covered - Avail. by Appeal</masterLabel>
            <translation><!-- Not Covered - Avail. by Appeal --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>On prescritpion drug list (PDL)</masterLabel>
            <translation><!-- On prescritpion drug list (PDL) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other (please specify)</masterLabel>
            <translation><!-- Other (please specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T2 Preferred Brand</masterLabel>
            <translation><!-- T2 Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T3 Non-Preferred Brand</masterLabel>
            <translation><!-- T3 Non-Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T3 Preferred Brand</masterLabel>
            <translation><!-- T3 Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T4 Non-Preferred Brand</masterLabel>
            <translation><!-- T4 Non-Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unsure/Don&apos;t Know</masterLabel>
            <translation><!-- Unsure/Don&apos;t Know --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q6. Formulary Flash --></label>
        <name>Q6_Formulary_Flash_BMS_US__c</name>
    </fields>
    <fields>
        <help><!-- Please enter how long until the plan typically reimburses new SC biologics? --></help>
        <label><!-- Q6. Orencia Profiling --></label>
        <name>Q6_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>3 Months</masterLabel>
            <translation><!-- 3 Months --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>6 Months</masterLabel>
            <translation><!-- 6 Months --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other (enter in comments)</masterLabel>
            <translation><!-- Other (enter in comments) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Requires P&amp;T review</masterLabel>
            <translation><!-- Requires P&amp;T review --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Upon Approval</masterLabel>
            <translation><!-- Upon Approval --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q7. Approved Sprycel --></label>
        <name>Q7_Approved_Sprycel_BMS_US__c</name>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not sure</masterLabel>
            <translation><!-- Not sure --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q7. Comments --></label>
        <name>Q7_Comments__c</name>
    </fields>
    <fields>
        <help><!-- Comments for Q7. --></help>
        <label><!-- Q7. Comments --></label>
        <name>Q7_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- Please enter the availability of a third NOAC trigger selection of a preferred agent by this customer --></help>
        <label><!-- Q7. Eliquis Assess --></label>
        <name>Q7_Eliquis_Assess_BMS_US__c</name>
        <picklistValues>
            <masterLabel>No, same mgt. for all NOACs</masterLabel>
            <translation><!-- No, same mgt. for all NOACs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No, unlikely</masterLabel>
            <translation><!-- No, unlikely --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unsure/Don&apos;t Know</masterLabel>
            <translation><!-- Unsure/Don&apos;t Know --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes, definitely</masterLabel>
            <translation><!-- Yes, definitely --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes, somewhat likely</masterLabel>
            <translation><!-- Yes, somewhat likely --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q7. Eliquis --></label>
        <name>Q7_Eliquis_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Other (please specify)</masterLabel>
            <translation><!-- Other (please specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PA plus Step Edit</masterLabel>
            <translation><!-- PA plus Step Edit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prior Authorization (PA)</masterLabel>
            <translation><!-- Prior Authorization (PA) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Quantity Limit</masterLabel>
            <translation><!-- Quantity Limit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Step Edit</masterLabel>
            <translation><!-- Step Edit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unrestricted</masterLabel>
            <translation><!-- Unrestricted --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unsure/Don&apos;t Know</masterLabel>
            <translation><!-- Unsure/Don&apos;t Know --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q7. Eliquis --></label>
        <name>Q7_Eliquis_Form_Flash_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Other (please specify)</masterLabel>
            <translation><!-- Other (please specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PA plus Step Edit</masterLabel>
            <translation><!-- PA plus Step Edit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prior Authorization (PA)</masterLabel>
            <translation><!-- Prior Authorization (PA) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Quantity Limit</masterLabel>
            <translation><!-- Quantity Limit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Step Edit</masterLabel>
            <translation><!-- Step Edit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unrestricted</masterLabel>
            <translation><!-- Unrestricted --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unsure/Don&apos;t Know</masterLabel>
            <translation><!-- Unsure/Don&apos;t Know --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q7. Formulary Flash --></label>
        <name>Q7_Formulary_Flash_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Gain</masterLabel>
            <translation><!-- Gain --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lose</masterLabel>
            <translation><!-- Lose --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Maintain</masterLabel>
            <translation><!-- Maintain --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Maintain w/Competitor Change</masterLabel>
            <translation><!-- Maintain w/Competitor Change --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Please record whether the pharmacy director/audience was favorable to the Orencia SC Value Proposition? --></help>
        <label><!-- Q7. Orencia Profiling --></label>
        <name>Q7_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Neutral, please explain in comments</masterLabel>
            <translation><!-- Neutral, please explain in comments --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No, please explain in comments</masterLabel>
            <translation><!-- No, please explain in comments --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other, please explain in comments</masterLabel>
            <translation><!-- Other, please explain in comments --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes, please explain in comments</masterLabel>
            <translation><!-- Yes, please explain in comments --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q8. Approved Sprycel --></label>
        <name>Q8_Approved_Sprycel__c</name>
        <picklistValues>
            <masterLabel>Evidence of issue in CML</masterLabel>
            <translation><!-- Evidence of issue in CML --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Evidence of issue in other TAs</masterLabel>
            <translation><!-- Evidence of issue in other TAs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No change in account risk</masterLabel>
            <translation><!-- No change in account risk --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other, please comment</masterLabel>
            <translation><!-- Other, please comment --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q8. Comments --></label>
        <name>Q8_Comments__c</name>
    </fields>
    <fields>
        <help><!-- Comments for Q8. --></help>
        <label><!-- Q8. Comments --></label>
        <name>Q8_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- Please record how influential a differentiated Eliquis value proposition will be to other NOACs for access --></help>
        <label><!-- Q8. Eliquis Assess --></label>
        <name>Q8_Eliquis_Assess_BMS_US__c</name>
        <picklistValues>
            <masterLabel>1- Highly influential</masterLabel>
            <translation><!-- 1- Highly influential --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>2- Moderately influential</masterLabel>
            <translation><!-- 2- Moderately influential --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>3- Somewhat influential</masterLabel>
            <translation><!-- 3- Somewhat influential --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>4 -Not influential</masterLabel>
            <translation><!-- 4 -Not influential --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q8. Eliquis --></label>
        <name>Q8_Eliquis_BMS_US__c</name>
    </fields>
    <fields>
        <label><!-- Q8. Eliquis --></label>
        <name>Q8_Eliquis_Form_Flash_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Non-prescription drug list (PDL)</masterLabel>
            <translation><!-- Non-prescription drug list (PDL) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not Covered</masterLabel>
            <translation><!-- Not Covered --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>On prescritpion drug list (PDL)</masterLabel>
            <translation><!-- On prescritpion drug list (PDL) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other (please specify)</masterLabel>
            <translation><!-- Other (please specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Tier 2 Preferred</masterLabel>
            <translation><!-- Tier 2 Preferred --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Tier 3 Non-Preferred</masterLabel>
            <translation><!-- Tier 3 Non-Preferred --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Tier 3 Preferred</masterLabel>
            <translation><!-- Tier 3 Preferred --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Tier 4 Non-Preferred</masterLabel>
            <translation><!-- Tier 4 Non-Preferred --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unsure/don’t know</masterLabel>
            <translation><!-- Unsure/don’t know --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Please enter the previous Formulary Status or Medical Policy --></help>
        <label><!-- Q8. Formulary Flash --></label>
        <name>Q8_Formulary_Flash_BMS_US__c</name>
        <picklistValues>
            <masterLabel>No Medical Policy, PA</masterLabel>
            <translation><!-- No Medical Policy, PA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No Medical Policy, no PA</masterLabel>
            <translation><!-- No Medical Policy, no PA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Non-PDL</masterLabel>
            <translation><!-- Non-PDL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nopolicyconsist w/labelpendP&amp;T</masterLabel>
            <translation><!-- Nopolicyconsist w/labelpendP&amp;T --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not Covered</masterLabel>
            <translation><!-- Not Covered --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other (see comments)</masterLabel>
            <translation><!-- Other (see comments) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PDL</masterLabel>
            <translation><!-- PDL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Policy consistent w/label noPA</masterLabel>
            <translation><!-- Policy consistent w/label noPA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Policy consistent w/label, PA</masterLabel>
            <translation><!-- Policy consistent w/label, PA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Policy more restrictive, PA</masterLabel>
            <translation><!-- Policy more restrictive, PA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Policy more restrictive, no PA</masterLabel>
            <translation><!-- Policy more restrictive, no PA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T1 Generic</masterLabel>
            <translation><!-- T1 Generic --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T1 Preferred Generic</masterLabel>
            <translation><!-- T1 Preferred Generic --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T2 Non-preferred Generic</masterLabel>
            <translation><!-- T2 Non-preferred Generic --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T2 Preferred Brand</masterLabel>
            <translation><!-- T2 Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T3 Non-preferred Brand</masterLabel>
            <translation><!-- T3 Non-preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T3 Preferred Brand</masterLabel>
            <translation><!-- T3 Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T4 Non-preferred brand</masterLabel>
            <translation><!-- T4 Non-preferred brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T4 Specialty Tier</masterLabel>
            <translation><!-- T4 Specialty Tier --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T5 Specialty Tier</masterLabel>
            <translation><!-- T5 Specialty Tier --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Please enter What the most compelling attribute of the Value Proposition was? --></help>
        <label><!-- Q8. Orencia Profiling --></label>
        <name>Q8_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Consistent safety</masterLabel>
            <translation><!-- Consistent safety --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>High retention</masterLabel>
            <translation><!-- High retention --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Non anti-TNF SC</masterLabel>
            <translation><!-- Non anti-TNF SC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Sustained efficacy</masterLabel>
            <translation><!-- Sustained efficacy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unique MOA</masterLabel>
            <translation><!-- Unique MOA --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q9. Approved Sprycel --></label>
        <name>Q9_Approved_Sprycel_BMS_US__c</name>
        <picklistValues>
            <masterLabel>High</masterLabel>
            <translation><!-- High --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Low</masterLabel>
            <translation><!-- Low --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Medium</masterLabel>
            <translation><!-- Medium --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q9. Comments --></label>
        <name>Q9_Comments__c</name>
    </fields>
    <fields>
        <help><!-- Comments for Q9. --></help>
        <label><!-- Q9. Comments --></label>
        <name>Q9_Comments_generic__c</name>
    </fields>
    <fields>
        <help><!-- Please record how influential Eliquis cost, relative to other NOACs, will be in gaining Eliquis access --></help>
        <label><!-- Q9. Eliquis Assess --></label>
        <name>Q9_Eliquis_Assess_BMS_US__c</name>
        <picklistValues>
            <masterLabel>1- Highly influential</masterLabel>
            <translation><!-- 1- Highly influential --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>2- Moderately influential</masterLabel>
            <translation><!-- 2- Moderately influential --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>3- Somewhat influential</masterLabel>
            <translation><!-- 3- Somewhat influential --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>4- Not influential</masterLabel>
            <translation><!-- 4- Not influential --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q9. Eliquis --></label>
        <name>Q9_Eliquis_BMS_US__c</name>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unsure/Don&apos;t Know</masterLabel>
            <translation><!-- Unsure/Don&apos;t Know --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Q9. Eliquis --></label>
        <name>Q9_Eliquis_Form_Flash_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PA Plus Step Edit</masterLabel>
            <translation><!-- PA Plus Step Edit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prior authorization</masterLabel>
            <translation><!-- Prior authorization --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Quantity Limit</masterLabel>
            <translation><!-- Quantity Limit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Step Edit</masterLabel>
            <translation><!-- Step Edit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unrestricted</masterLabel>
            <translation><!-- Unrestricted --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unsure/don’t know</masterLabel>
            <translation><!-- Unsure/don’t know --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Please enter the new Formulary Status or Medical Policy --></help>
        <label><!-- Q9. Formulary Flash --></label>
        <name>Q9_Formulary_Flash_BMS_US__c</name>
        <picklistValues>
            <masterLabel>No Medical Policy, PA</masterLabel>
            <translation><!-- No Medical Policy, PA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No Medical Policy, no PA</masterLabel>
            <translation><!-- No Medical Policy, no PA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Non-PDL</masterLabel>
            <translation><!-- Non-PDL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nopolicyconsist w/labelpendP&amp;T</masterLabel>
            <translation><!-- Nopolicyconsist w/labelpendP&amp;T --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not Covered</masterLabel>
            <translation><!-- Not Covered --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other (see comments)</masterLabel>
            <translation><!-- Other (see comments) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PDL</masterLabel>
            <translation><!-- PDL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Policy consistent w/label noPA</masterLabel>
            <translation><!-- Policy consistent w/label noPA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Policy consistent w/label, PA</masterLabel>
            <translation><!-- Policy consistent w/label, PA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Policy more restrictive, PA</masterLabel>
            <translation><!-- Policy more restrictive, PA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Policy more restrictive, no PA</masterLabel>
            <translation><!-- Policy more restrictive, no PA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T1 Generic</masterLabel>
            <translation><!-- T1 Generic --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T1 Preferred Generic</masterLabel>
            <translation><!-- T1 Preferred Generic --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T2 Non-preferred Generic</masterLabel>
            <translation><!-- T2 Non-preferred Generic --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T2 Preferred Brand</masterLabel>
            <translation><!-- T2 Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T3 Non-preferred Brand</masterLabel>
            <translation><!-- T3 Non-preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T3 Preferred Brand</masterLabel>
            <translation><!-- T3 Preferred Brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T4 Non-preferred brand</masterLabel>
            <translation><!-- T4 Non-preferred brand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T4 Specialty Tier</masterLabel>
            <translation><!-- T4 Specialty Tier --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T5 Specialty Tier</masterLabel>
            <translation><!-- T5 Specialty Tier --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Please enter the least compelling attribute of the Value Proposition --></help>
        <label><!-- Q9. Orencia Profiling --></label>
        <name>Q9_Orencia_Profiling_BMS_US__c</name>
        <picklistValues>
            <masterLabel>Consistent safety</masterLabel>
            <translation><!-- Consistent safety --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>High retention</masterLabel>
            <translation><!-- High retention --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Non anti-TNF SC</masterLabel>
            <translation><!-- Non anti-TNF SC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Sustained efficacy</masterLabel>
            <translation><!-- Sustained efficacy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unique MOA</masterLabel>
            <translation><!-- Unique MOA --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Q. Are you aware of any reasons biomarker tests are not ordered in time to make a decision for 1st line treatment of mCRC? --></help>
        <label><!-- Q. Any reason tests not ordered in time? --></label>
        <name>Q_Any_reason_tests_not_ordered_in_time__c</name>
        <picklistValues>
            <masterLabel>Anti-EGFR not used 1st-line</masterLabel>
            <translation><!-- Anti-EGFR not used 1st-line --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not part of protocol</masterLabel>
            <translation><!-- Not part of protocol --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Takes too long for test results</masterLabel>
            <translation><!-- Takes too long for test results --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Q. Is there a protocol for biomarker testing in patients with mCRC at your institution? If not, is there a prevailing practice as to when it occurs? --></help>
        <label><!-- Q. Biomarker Testing for mCRC Patients? --></label>
        <name>Q_Biomarker_Testing_for_mCRC__c</name>
        <picklistValues>
            <masterLabel>No protocol, and biomarker testing varies widely</masterLabel>
            <translation><!-- No protocol, and biomarker testing varies widely --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No protocol, but biomarker testing is fairly consistent</masterLabel>
            <translation><!-- No protocol, but biomarker testing is fairly consistent --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Q. What is your educational and training background? --></help>
        <label><!-- Q. Educational and training background? --></label>
        <name>Q_Educational_and_training_background__c</name>
        <picklistValues>
            <masterLabel>PharmD, with no specialty oncology training or BCOP designation</masterLabel>
            <translation><!-- PharmD, with no specialty oncology training or BCOP designation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PharmD, with specialty oncology training or BCOP designation</masterLabel>
            <translation><!-- PharmD, with specialty oncology training or BCOP designation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>RPh</masterLabel>
            <translation><!-- RPh --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>RPh, with specialty oncology training</masterLabel>
            <translation><!-- RPh, with specialty oncology training --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Q. What are your educational needs regarding biomarkers in mCRC? --></help>
        <label><!-- Q. Educational needs for biomarkers? --></label>
        <name>Q_Educational_needs_for_biomarkers__c</name>
        <picklistValues>
            <masterLabel>Clinical validity of biomarkers</masterLabel>
            <translation><!-- Clinical validity of biomarkers --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>How to set up biomarker protocols</masterLabel>
            <translation><!-- How to set up biomarker protocols --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Testing methods &amp; differences</masterLabel>
            <translation><!-- Testing methods &amp; differences --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Q. What information is relied upon for interpreting the clinical validity/usefulness of biomarker tests? --></help>
        <label><!-- Q. Info used to interpret results? --></label>
        <name>Q_Info_used_to_interpret_results__c</name>
        <picklistValues>
            <masterLabel>Discussion with tumor board</masterLabel>
            <translation><!-- Discussion with tumor board --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Formulary or other committee</masterLabel>
            <translation><!-- Formulary or other committee --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Guidelines, e.g. NCCN</masterLabel>
            <translation><!-- Guidelines, e.g. NCCN --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Interpretation given by test co.</masterLabel>
            <translation><!-- Interpretation given by test co. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Own analysis of literature</masterLabel>
            <translation><!-- Own analysis of literature --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Review articles</masterLabel>
            <translation><!-- Review articles --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Q. How often do you interact with other members of the patient management team? --></help>
        <label><!-- Q. Interaction with management team? --></label>
        <name>Q_Interaction_with_management_team__c</name>
        <picklistValues>
            <masterLabel>Daily</masterLabel>
            <translation><!-- Daily --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monthly</masterLabel>
            <translation><!-- Monthly --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Weekly</masterLabel>
            <translation><!-- Weekly --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Q. How are you involved in the management of patients with mCRC at your institution? --></help>
        <label><!-- Q. Involvement in patient management? --></label>
        <name>Q_Involvement_in_patient_management__c</name>
        <picklistValues>
            <masterLabel>AE management</masterLabel>
            <translation><!-- AE management --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Formulary decision maker</masterLabel>
            <translation><!-- Formulary decision maker --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Patient counseling</masterLabel>
            <translation><!-- Patient counseling --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Treatment recommendation/selection</masterLabel>
            <translation><!-- Treatment recommendation/selection --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Q. What is your preferred method of learning (self-study, CME dinner program, etc.)? --></help>
        <label><!-- Q. Preferred method of learning? --></label>
        <name>Q_Preferred_method_of_learning__c</name>
        <picklistValues>
            <masterLabel>Annual congresses/meetings</masterLabel>
            <translation><!-- Annual congresses/meetings --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IME/CME</masterLabel>
            <translation><!-- IME/CME --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Medical websites</masterLabel>
            <translation><!-- Medical websites --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Pathologist-specific journals</masterLabel>
            <translation><!-- Pathologist-specific journals --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Scientific journals (e.g., JAMA)</masterLabel>
            <translation><!-- Scientific journals (e.g., JAMA) --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Q. What is your institution’s protocol for 1st line treatment of mCRC? --></help>
        <label><!-- Q. Protocol for 1st line treat. of mCRC? --></label>
        <name>Q_Protocol_for_1st_line_treat_of_mCRC__c</name>
        <picklistValues>
            <masterLabel>CapeOx +/- bevacizumab</masterLabel>
            <translation><!-- CapeOx +/- bevacizumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>FOLFIRI + cetuximab</masterLabel>
            <translation><!-- FOLFIRI + cetuximab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>FOLFIRI alone</masterLabel>
            <translation><!-- FOLFIRI alone --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>FOLFOX + bevacizumab</masterLabel>
            <translation><!-- FOLFOX + bevacizumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>FOLFOX + panitumumab</masterLabel>
            <translation><!-- FOLFOX + panitumumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>FOLFOX alone.</masterLabel>
            <translation><!-- FOLFOX alone. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Q. What was your role, if any, in the development of the biomarker testing protocol for mCRC at your institution? --></help>
        <label><!-- Q. Role in development of testing? --></label>
        <name>Q_Role_in_development_of_testing__c</name>
        <picklistValues>
            <masterLabel>Advisory role/provided data but not a decision maker</masterLabel>
            <translation><!-- Advisory role/provided data but not a decision maker --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Key decision maker</masterLabel>
            <translation><!-- Key decision maker --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No role</masterLabel>
            <translation><!-- No role --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Q. Are biomarker tests ordered and received in time to make decisions for 1st line treatment of mCRC? --></help>
        <label><!-- Q. Tests ordered &amp; received in time? --></label>
        <name>Q_Tests_ordered_received_in_time__c</name>
        <picklistValues>
            <masterLabel>Always</masterLabel>
            <translation><!-- Always --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Never</masterLabel>
            <translation><!-- Never --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Sometimes</masterLabel>
            <translation><!-- Sometimes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Q. When are biomarker tests usually incorporated in mCRC patients at your institution? --></help>
        <label><!-- Q.When are biomarket tests incorporated? --></label>
        <name>Q_Wen_are_biomarket_test_incorporated__c</name>
        <picklistValues>
            <masterLabel>After failure of first-line therapy</masterLabel>
            <translation><!-- After failure of first-line therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Before first-line therapy</masterLabel>
            <translation><!-- Before first-line therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>During first-line therapy</masterLabel>
            <translation><!-- During first-line therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Only before giving an anti-EGFR</masterLabel>
            <translation><!-- Only before giving an anti-EGFR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Rarely</masterLabel>
            <translation><!-- Rarely --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Q. What was your role, if any, in the development of the treatment protocol for 1st line mCRC? --></help>
        <label><!-- Q. What was your role in development? --></label>
        <name>Q_What_was_your_role_in_development__c</name>
        <picklistValues>
            <masterLabel>Advisory role, not a decision maker</masterLabel>
            <translation><!-- Advisory role, not a decision maker --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Key decision maker</masterLabel>
            <translation><!-- Key decision maker --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No role</masterLabel>
            <translation><!-- No role --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Q. Where do you go for information?  What information sources do you consider reliable? --></help>
        <label><!-- Q. Where do you go for information? --></label>
        <name>Q_Where_do_you_go_for_information__c</name>
        <picklistValues>
            <masterLabel>Annual congresses/meetings</masterLabel>
            <translation><!-- Annual congresses/meetings --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IME/CME</masterLabel>
            <translation><!-- IME/CME --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Medical websites</masterLabel>
            <translation><!-- Medical websites --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Pharmacist-specific journals</masterLabel>
            <translation><!-- Pharmacist-specific journals --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Scientific journals (e.g. JAMA)</masterLabel>
            <translation><!-- Scientific journals (e.g. JAMA) --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Q. Which biomarker tests are ordered for patients with mCRC at your institution? --></help>
        <label><!-- Q. Which biomarker tests are ordered? --></label>
        <name>Q_Which_biomarker_tests_are_ordered__c</name>
        <picklistValues>
            <masterLabel>Amphiregulin/epiregulin</masterLabel>
            <translation><!-- Amphiregulin/epiregulin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BRAF</masterLabel>
            <translation><!-- BRAF --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ERCC1</masterLabel>
            <translation><!-- ERCC1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>KRAS</masterLabel>
            <translation><!-- KRAS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PI3K</masterLabel>
            <translation><!-- PI3K --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PTEN</masterLabel>
            <translation><!-- PTEN --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Q. Which professional associations do you look to for information or resources? --></help>
        <label><!-- Q. Which prof. assoc. do you look to? --></label>
        <name>Q_Which_prof_assoc_do_you_look_to__c</name>
    </fields>
    <fields>
        <help><!-- Q. Who interprets the biomarker test results? Does anyone make recommendations regarding treatment decisions based on the results of the testing? --></help>
        <label><!-- Q.Who interprets biomarket test results? --></label>
        <name>Q_Who_interprets_biomarket_test_results__c</name>
        <picklistValues>
            <masterLabel>Path adds interpretation to test results</masterLabel>
            <translation><!-- Path adds interpretation to test results --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Path. provides tx impact</masterLabel>
            <translation><!-- Path. provides tx impact --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Path. reads results only</masterLabel>
            <translation><!-- Path. reads results only --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Test co. gives results &amp; tx impact</masterLabel>
            <translation><!-- Test co. gives results &amp; tx impact --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Test co. provides results only</masterLabel>
            <translation><!-- Test co. provides results only --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Q. How many years of oncology experience do you have? --></help>
        <label><!-- Q. Years of oncology experience? --></label>
        <name>Q_Years_of_oncology_experience__c</name>
    </fields>
    <fields>
        <help>Hoe groot is de kans dat de KOL patiëntprofieldocumenten zal gebruiken?</help>
        <label>Patiëntprofielen RL</label>
        <name>RL_Patient_Profiles__c</name>
        <picklistValues>
            <masterLabel>Somewhat Likely</masterLabel>
            <translation>Enigszins waarschijnlijk</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unlikely</masterLabel>
            <translation>Onwaarschijnlijk</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Very Likely</masterLabel>
            <translation>Zeer waarschijnlijk</translation>
        </picklistValues>
    </fields>
    <fields>
        <help>Hoe groot is de kans dat de KOL onderzoeksresultaten voor Restolar zal gebruiken in bezoeken met collega&apos;s?</help>
        <label>Onderzoekstoepassing RL</label>
        <name>RL_Study_Leverage__c</name>
        <picklistValues>
            <masterLabel>Somewhat Likely</masterLabel>
            <translation>Enigszins waarschijnlijk</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unlikely</masterLabel>
            <translation>Onwaarschijnlijk</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Very Likely</masterLabel>
            <translation>Zeer waarschijnlijk</translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Forced adjustment of Doctor rating (RM approval required) (Upgrade +1, Downgrade -1) --></help>
        <label><!-- Rating adjustment --></label>
        <name>Rating_adjustment_BMS_CA__c</name>
    </fields>
    <fields>
        <help><!-- How does the practice manage Reimbursement challenges? --></help>
        <label><!-- Reimbursement Challenges Management --></label>
        <name>Reimbursement_Challenges_Management_BMS__c</name>
        <picklistValues>
            <masterLabel>Administer product at alternate site</masterLabel>
            <translation><!-- Administer product at alternate site --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Avoid products with Temp J codes</masterLabel>
            <translation><!-- Avoid products with Temp J codes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Offer services for patients proactively</masterLabel>
            <translation><!-- Offer services for patients proactively --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Only use products on formulary</masterLabel>
            <translation><!-- Only use products on formulary --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Utilize other Ptnt Assistance prgrms</masterLabel>
            <translation><!-- Utilize other Ptnt Assistance prgrms --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Utilizes Reimbursement Specialists</masterLabel>
            <translation><!-- Utilizes Reimbursement Specialists --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- How does the account prefer to be educated on reimbursement support services offered by the manufacturer? (Choose all that apply) --></help>
        <label><!-- Reimbursement support education method --></label>
        <name>Reimbursement_support_education_BMS__c</name>
        <picklistValues>
            <masterLabel>3rd party support</masterLabel>
            <translation><!-- 3rd party support --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Does not need support</masterLabel>
            <translation><!-- Does not need support --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Hard copy toolkit</masterLabel>
            <translation><!-- Hard copy toolkit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Live support</masterLabel>
            <translation><!-- Live support --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Web site</masterLabel>
            <translation><!-- Web site --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Related Organization (Not in InterAct) --></label>
        <name>Related_Organization_Not_in_InterAct__c</name>
    </fields>
    <fields>
        <help><!-- Lookup the Organization to which this Individual is related. If the Organization does not exit in InterAct, please type the name of the Organization in the Related Organization (Not In InterAct) field. --></help>
        <label><!-- Related Organization (in InterAct) --></label>
        <name>Related_Organization_in_InterAct__c</name>
        <relationshipLabel><!-- Surveys (Related Organization (in InterAct)) --></relationshipLabel>
    </fields>
    <fields>
        <help>In hoeverre is de KOL bereid onderzoek te gebruiken?</help>
        <label>Onderzoeksfocus</label>
        <name>Research_Focus__c</name>
        <picklistValues>
            <masterLabel>Heavily</masterLabel>
            <translation>Ernstig</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not at all</masterLabel>
            <translation>Helemaal niet</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Slightly</masterLabel>
            <translation>Enigszins</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Somewhat</masterLabel>
            <translation>Matig</translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- What are this prescriber&apos;s research interest and / or publications? --></help>
        <label><!-- Reserch interests and/or publications --></label>
        <name>Reserch_interests_or_publications_BMS__c</name>
        <picklistValues>
            <masterLabel>Average</masterLabel>
            <translation><!-- Average --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>High</masterLabel>
            <translation><!-- High --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lower than average</masterLabel>
            <translation><!-- Lower than average --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Very High</masterLabel>
            <translation><!-- Very High --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Run Time --></label>
        <name>Run_Time_ORENCIA_BMS__c</name>
    </fields>
    <fields>
        <help><!-- Approximately how many unique SCCHN patients per year does the prescriber treat with Systemic Therapy? --></help>
        <label><!-- SCCHN ptnts/year trtd w/ Systemic Thrpy? --></label>
        <name>SCCHN_ptnts_year_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Sales Force Name --></label>
        <name>Sales_Force_Name_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Second Health Plan --></label>
        <name>Second_Health_Plan_BMS__c</name>
        <picklistValues>
            <masterLabel>Aetna</masterLabel>
            <translation><!-- Aetna --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BCBS</masterLabel>
            <translation><!-- BCBS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Cigna</masterLabel>
            <translation><!-- Cigna --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>United Health Care</masterLabel>
            <translation><!-- United Health Care --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Well Point / Anthem</masterLabel>
            <translation><!-- Well Point / Anthem --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Does your practice have specific disease treatment guidelines? --></help>
        <label><!-- Specific disease treatment guidelines? --></label>
        <name>Specific_disease_treatment_BMS__c</name>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes, for all tumor types</masterLabel>
            <translation><!-- Yes, for all tumor types --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes, for limited tumor types</masterLabel>
            <translation><!-- Yes, for limited tumor types --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Territory Business Code --></label>
        <name>Territory_Business_Code_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Territory Description --></label>
        <name>Territory_Description_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Territory Function Code --></label>
        <name>Territory_Function_Code_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Territory Region Code BMS --></label>
        <name>Territory_Region_Code_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Territory Sales Area Code BMS --></label>
        <name>Territory_Sales_Area_Code_BMS__c</name>
    </fields>
    <fields>
        <help><!-- Does prescriber test for KRAS at diagnosis of mCRC? --></help>
        <label><!-- Test for KRAS as diagnosis of mCRC? --></label>
        <name>Test_for_KRAS_as_diagnosis_of_mCRC_BMS__c</name>
        <picklistValues>
            <masterLabel>Tests at diagnosis of mCRC</masterLabel>
            <translation><!-- Tests at diagnosis of mCRC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Tests in 2nd line when considering ERBITUX</masterLabel>
            <translation><!-- Tests in 2nd line when considering ERBITUX --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Tests in later lines when considering ERBITUX</masterLabel>
            <translation><!-- Tests in later lines when considering ERBITUX --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Therapeutic Area --></label>
        <name>Therapeutic_Area_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Third Health Plan --></label>
        <name>Third_Health_Plan_BMS__c</name>
        <picklistValues>
            <masterLabel>Aetna</masterLabel>
            <translation><!-- Aetna --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BCBS</masterLabel>
            <translation><!-- BCBS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Cigna</masterLabel>
            <translation><!-- Cigna --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>United Health Care</masterLabel>
            <translation><!-- United Health Care --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Well Point / Anthem</masterLabel>
            <translation><!-- Well Point / Anthem --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Please enter the % of time that the prescriber spends in an office setting. --></help>
        <label><!-- Time in office setting --></label>
        <name>Time_in_office_setting_BMS__c</name>
        <picklistValues>
            <masterLabel>0%</masterLabel>
            <translation><!-- 0% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>1-10%</masterLabel>
            <translation><!-- 1-10% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>11-20%</masterLabel>
            <translation><!-- 11-20% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>21-30%</masterLabel>
            <translation><!-- 21-30% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>31-40%</masterLabel>
            <translation><!-- 31-40% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>41-50%</masterLabel>
            <translation><!-- 41-50% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>51-60%</masterLabel>
            <translation><!-- 51-60% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>61-70%</masterLabel>
            <translation><!-- 61-70% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>71-80%</masterLabel>
            <translation><!-- 71-80% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>81-90%</masterLabel>
            <translation><!-- 81-90% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>91-100%</masterLabel>
            <translation><!-- 91-100% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time, but will investigate</masterLabel>
            <translation><!-- Don&apos;t know at this time, but will investigate --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Please enter the % of time that the prescriber spends in an academic center --></help>
        <label><!-- Time spent in an academic center --></label>
        <name>Time_spent_in_an_academic_center_BMS__c</name>
        <picklistValues>
            <masterLabel>0%</masterLabel>
            <translation><!-- 0% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>1-10%</masterLabel>
            <translation><!-- 1-10% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>11-20%</masterLabel>
            <translation><!-- 11-20% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>21-30%</masterLabel>
            <translation><!-- 21-30% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>31-40%</masterLabel>
            <translation><!-- 31-40% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>41-50%</masterLabel>
            <translation><!-- 41-50% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>51-60%</masterLabel>
            <translation><!-- 51-60% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>61-70%</masterLabel>
            <translation><!-- 61-70% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>71-80%</masterLabel>
            <translation><!-- 71-80% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>81-90%</masterLabel>
            <translation><!-- 81-90% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>91-100%</masterLabel>
            <translation><!-- 91-100% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time, but will investigate</masterLabel>
            <translation><!-- Don&apos;t know at this time, but will investigate --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Please enter the % of time that the prescriber spends in an non-academic hospital setting. --></help>
        <label><!-- Time spent in non-academic hospital --></label>
        <name>Time_spent_in_non_academic_hospital_BMS__c</name>
        <picklistValues>
            <masterLabel>0%</masterLabel>
            <translation><!-- 0% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>1-10%</masterLabel>
            <translation><!-- 1-10% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>11-20%</masterLabel>
            <translation><!-- 11-20% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>21-30%</masterLabel>
            <translation><!-- 21-30% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>31-40%</masterLabel>
            <translation><!-- 31-40% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>41-50%</masterLabel>
            <translation><!-- 41-50% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>51-60%</masterLabel>
            <translation><!-- 51-60% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>61-70%</masterLabel>
            <translation><!-- 61-70% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>71-80%</masterLabel>
            <translation><!-- 71-80% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>81-90%</masterLabel>
            <translation><!-- 81-90% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>91-100%</masterLabel>
            <translation><!-- 91-100% --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time, but will investigate</masterLabel>
            <translation><!-- Don&apos;t know at this time, but will investigate --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Does the prescriber treat patients with SCCHN? --></help>
        <label><!-- Treat patients with SCCHN? --></label>
        <name>Treat_patients_with_SCCHN_BMS__c</name>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help>Welke behandeling heeft de absolute voorkeur van de arts?</help>
        <label>Behandelingsvoorkeuren</label>
        <name>Treatment_Preferences__c</name>
        <picklistValues>
            <masterLabel>Chemo</masterLabel>
            <translation>Chemotherapie</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Chemo &amp; Radiation</masterLabel>
            <translation>Chemotherapie en bestraling</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Diet/Nutrition/Alternative</masterLabel>
            <translation>Dieet/voeding/alternatief</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Radiation</masterLabel>
            <translation>Bestraling</translation>
        </picklistValues>
    </fields>
    <fields>
        <help>Hoeveel tumoren behandelt deze arts per jaar?</help>
        <label>Tumoren/jaar</label>
        <name>Treatment_Volume__c</name>
        <picklistValues>
            <masterLabel>0-50</masterLabel>
            <translation><!-- 0-50 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>100-150</masterLabel>
            <translation><!-- 100-150 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>150+</masterLabel>
            <translation><!-- 150+ --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>50-100</masterLabel>
            <translation><!-- 50-100 --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- How does this physician generally treat their SCCHN LRD patients who require systematic therapy? --></help>
        <label><!-- Treatment of SCCHN LRD patients? --></label>
        <name>Treatment_of_SCCHN_LRD_patients_BMS__c</name>
        <picklistValues>
            <masterLabel>Exclusively uses Platinum+RT in eligible LRD patients</masterLabel>
            <translation><!-- Exclusively uses Platinum+RT in eligible LRD patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Typically uses ERBITUX+RT appropriately across LRD patients</masterLabel>
            <translation><!-- Typically uses ERBITUX+RT appropriately across LRD patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Uses ERBITUX+RT in patients eligible but high rise (ex. Low PS, elderly, comorbidities)</masterLabel>
            <translation><!-- Uses ERBITUX+RT in patients eligible but high rise (ex. Low PS, elderly, comorbidities) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Uses ERBITUX+RT only in patients who are clearly platinum-ineligible</masterLabel>
            <translation><!-- Uses ERBITUX+RT only in patients who are clearly platinum-ineligible --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- This prescriber&apos;s treatment choices are highly influenced by: --></help>
        <label><!-- Trtmnt choices are highly influenced by: --></label>
        <name>Trtmnt_choices_are_highly_influenced_BMS__c</name>
        <picklistValues>
            <masterLabel>Buying Group Pathway (i.e. USON)</masterLabel>
            <translation><!-- Buying Group Pathway (i.e. USON) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Institutional Pathway/Guideline</masterLabel>
            <translation><!-- Institutional Pathway/Guideline --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NCCN Guidelines</masterLabel>
            <translation><!-- NCCN Guidelines --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Payer Pathways</masterLabel>
            <translation><!-- Payer Pathways --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reimbursement</masterLabel>
            <translation><!-- Reimbursement --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help>In de behandeling van welk type tumoren is deze arts gespecialiseerd?  U kunt er maximaal 3 kiezen.</help>
        <label>Tumortypen</label>
        <name>Tumor_Types__c</name>
        <picklistValues>
            <masterLabel>Bone</masterLabel>
            <translation>Bot</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Breast</masterLabel>
            <translation>Borst</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Colon</masterLabel>
            <translation>Darm</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Kidney</masterLabel>
            <translation>Nier</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Liver</masterLabel>
            <translation>Lever</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lung</masterLabel>
            <translation>Long</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ovary/Uterus/Cervix</masterLabel>
            <translation>Eierstokken/baarmoeder/baarmoederhals</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Pancreas</masterLabel>
            <translation>Alvleesklier</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prostate</masterLabel>
            <translation>Prostaat</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Stomach</masterLabel>
            <translation>Maag</translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Indicate the type of access restriction (if any) for this prescriber? --></help>
        <label><!-- Type of access restriction --></label>
        <name>Type_of_access_restriction_BMS__c</name>
        <picklistValues>
            <masterLabel>Difficult to travel to physician/account</masterLabel>
            <translation><!-- Difficult to travel to physician/account --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Good Access (Open access at will)</masterLabel>
            <translation><!-- Good Access (Open access at will) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Limited Access (Frequency limitation - appointment only)</masterLabel>
            <translation><!-- Limited Access (Frequency limitation - appointment only) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No Access (Prescriber will not see any reps)</masterLabel>
            <translation><!-- No Access (Prescriber will not see any reps) --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- What is customers level of understanding of SPRYCEL&apos;s AE profile? --></help>
        <label><!-- Understanding of SPRYCEL&apos;s AE profile? --></label>
        <name>Understanding_of_SPRYCELs_AE_profile_BMS__c</name>
        <picklistValues>
            <masterLabel>Is not aware of SPRYCEL AE profile and management recommendations</masterLabel>
            <translation><!-- Is not aware of SPRYCEL AE profile and management recommendations --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Understands AE profile but is uncomfortable managing Aes</masterLabel>
            <translation><!-- Understands AE profile but is uncomfortable managing Aes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Understands how to identify and properly manage SPRYCEL Aes</masterLabel>
            <translation><!-- Understands how to identify and properly manage SPRYCEL Aes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Does the prescriber routinely use ERBITUX in 2nd line, in combination? --></help>
        <label><!-- Use ERBITUX in 2nd line, in combination? --></label>
        <name>Use_ERBITUX_in_2nd_line_BMS__c</name>
        <picklistValues>
            <masterLabel>In combination but only in 3rd line</masterLabel>
            <translation><!-- In combination but only in 3rd line --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not regularly</masterLabel>
            <translation><!-- Not regularly --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Only uses in 3rd line as single agent</masterLabel>
            <translation><!-- Only uses in 3rd line as single agent --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Routinely</masterLabel>
            <translation><!-- Routinely --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- To what extent does the prescriber use the dose reduction schedule to manage toxicities? --></help>
        <label><!-- Use dose reduction to mng toxicities? --></label>
        <name>Use_dose_reduction_BMS__c</name>
        <picklistValues>
            <masterLabel>Consistently uses 1 dose reductions</masterLabel>
            <translation><!-- Consistently uses 1 dose reductions --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Consistently uses 2 dose reductions</masterLabel>
            <translation><!-- Consistently uses 2 dose reductions --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Rarely uses</masterLabel>
            <translation><!-- Rarely uses --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Sometimes uses 1 or 2 dose reductions</masterLabel>
            <translation><!-- Sometimes uses 1 or 2 dose reductions --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Switches patients rather than dose reduce</masterLabel>
            <translation><!-- Switches patients rather than dose reduce --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Which best describes the use of Patient Materials in the practice? --></help>
        <label><!-- Use of Patient Materials --></label>
        <name>Use_of_Patient_Materials_BMS__c</name>
        <picklistValues>
            <masterLabel>Actively by Patient Educator or doctor to advocate to other HCPs the quality of the program</masterLabel>
            <translation><!-- Actively by Patient Educator or doctor to advocate to other HCPs the quality of the program --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Actively by the Patient Educator or doctor to show what is available to help patients</masterLabel>
            <translation><!-- Actively by the Patient Educator or doctor to show what is available to help patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not actively used</masterLabel>
            <translation><!-- Not actively used --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Passively makes materials available</masterLabel>
            <translation><!-- Passively makes materials available --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Are there any reasons that would cause the account to infuse specific patients at an alternate center vs. your practice? (Check all that apply) --></help>
        <label><!-- Use of an alternate center? --></label>
        <name>Use_of_an_alternate_center_BMS__c</name>
        <picklistValues>
            <masterLabel>Don&apos;t stock drug</masterLabel>
            <translation><!-- Don&apos;t stock drug --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Drug reimbursement is uncertain</masterLabel>
            <translation><!-- Drug reimbursement is uncertain --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>My site doesn&apos;t infuse</masterLabel>
            <translation><!-- My site doesn&apos;t infuse --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Patient preference</masterLabel>
            <translation><!-- Patient preference --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Does the prescriber use the recommended start dose of 40mg/m2? --></help>
        <label><!-- Prescriber uses recommended start dose? --></label>
        <name>Uses_recommended_start_dose_BMS__c</name>
        <picklistValues>
            <masterLabel>Almost always</masterLabel>
            <translation><!-- Almost always --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Almost never</masterLabel>
            <translation><!-- Almost never --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Frequently</masterLabel>
            <translation><!-- Frequently --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Infrequently</masterLabel>
            <translation><!-- Infrequently --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not Applicable</masterLabel>
            <translation><!-- Not Applicable --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Sometimes</masterLabel>
            <translation><!-- Sometimes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- When does the P&amp;T or Medical Review Committee typically review new products for oncology at this institution/practice? --></help>
        <label><!-- When are new products reviewed? --></label>
        <name>When_are_new_products_reviewed_BMS__c</name>
        <picklistValues>
            <masterLabel>At launch</masterLabel>
            <translation><!-- At launch --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Greater than 5 months</masterLabel>
            <translation><!-- Greater than 5 months --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Months 1 - 2</masterLabel>
            <translation><!-- Months 1 - 2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Months 3 - 5</masterLabel>
            <translation><!-- Months 3 - 5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- In which line of therapy is IXEMPRA typically used as monotherapy? --></help>
        <label><!-- Which line of Therapy is IXEMPRA used? --></label>
        <name>Which_line_of_Therapy_is_IXEMPRA_BMS__c</name>
        <picklistValues>
            <masterLabel>2nd line</masterLabel>
            <translation><!-- 2nd line --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>3rd line</masterLabel>
            <translation><!-- 3rd line --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>4th or 5th line</masterLabel>
            <translation><!-- 4th or 5th line --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Don&apos;t know at this time</masterLabel>
            <translation><!-- Don&apos;t know at this time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Never uses</masterLabel>
            <translation><!-- Never uses --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Rarely uses</masterLabel>
            <translation><!-- Rarely uses --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- From who do they currently order product? (Choose all that apply) --></help>
        <label><!-- Who do they order product from? --></label>
        <name>Who_do_they_order_product_from_BMS__c</name>
        <picklistValues>
            <masterLabel>AmeriSource Bergen</masterLabel>
            <translation><!-- AmeriSource Bergen --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Cardinal</masterLabel>
            <translation><!-- Cardinal --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>McKesson</masterLabel>
            <translation><!-- McKesson --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>McKesson Specialty</masterLabel>
            <translation><!-- McKesson Specialty --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Oncology Supply</masterLabel>
            <translation><!-- Oncology Supply --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other (Please Specify)</masterLabel>
            <translation><!-- Other (Please Specify) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>US Oncology</masterLabel>
            <translation><!-- US Oncology --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- If this HCP has seen unresectable or metastatic melanoma patients and not put them on YERVOY, why hasn&apos;t this HCP used YERVOY more often? (Choose all that apply) --></help>
        <label><!-- Why hasn&apos;t HCP used YERVOY more often? --></label>
        <name>Why_hasn_t_HCP_used_YERVOY_more_BMS__c</name>
        <picklistValues>
            <masterLabel>Cost or reimbursement to Account</masterLabel>
            <translation><!-- Cost or reimbursement to Account --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Feels YERVOY is too toxic</masterLabel>
            <translation><!-- Feels YERVOY is too toxic --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Haven&apos;t seen an appropriate patient</masterLabel>
            <translation><!-- Haven&apos;t seen an appropriate patient --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not compelled by YERVOY&apos;s efficacy</masterLabel>
            <translation><!-- Not compelled by YERVOY&apos;s efficacy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Product cost or reimbursement to patient</masterLabel>
            <translation><!-- Product cost or reimbursement to patient --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Will not Order from Oncology Supply</masterLabel>
            <translation><!-- Will not Order from Oncology Supply --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Will not order from McKesson</masterLabel>
            <translation><!-- Will not order from McKesson --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- If the practice has seen unresectable or metastatic melanoma patients and not put them on YERVOY, why hasn&apos;t this practice used YERVOY more often? (choose all that apply) --></help>
        <label><!-- Why hasn&apos;t Practice used YERVOY more? --></label>
        <name>Why_hasnt_Practice_used_Yervoy_BMS__c</name>
        <picklistValues>
            <masterLabel>Cost or reimbursement to Acct</masterLabel>
            <translation><!-- Cost or reimbursement to Acct --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Formulary issue within Account</masterLabel>
            <translation><!-- Formulary issue within Account --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Haven&apos;t seen an appropriate patient</masterLabel>
            <translation><!-- Haven&apos;t seen an appropriate patient --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Product cost or reimbursement to patient</masterLabel>
            <translation><!-- Product cost or reimbursement to patient --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Will not order from McKesson</masterLabel>
            <translation><!-- Will not order from McKesson --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Will not order from Oncology Supply</masterLabel>
            <translation><!-- Will not order from Oncology Supply --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- 1. Do you have infusion capabilities? --></label>
        <name>X1_Do_you_have_infusion_capabil_BMS_US__c</name>
    </fields>
    <fields>
        <label><!-- 2. Do you accept samples? --></label>
        <name>X2_Do_you_accept_samples_BMS_US__c</name>
    </fields>
    <fields>
        <label><!-- 3. Are &gt;25% of your patients adults? --></label>
        <name>X3_Are_25_of_your_patients_adults_BMS_US__c</name>
    </fields>
    <fields>
        <help><!-- Nbr of patients treated with Yervoy in past 12 months? --></help>
        <label><!-- Yervoy Patients --></label>
        <name>Yervoy_Patients_BMS_CA__c</name>
    </fields>
    <fields>
        <help><!-- Yervoy prescribing behavior (Unaware, Aware, Experienced) --></help>
        <label><!-- Yervoy Rx behavior --></label>
        <name>Yervoy_Rx_behavior_BMS_CA__c</name>
        <picklistValues>
            <masterLabel>Aware</masterLabel>
            <translation><!-- Aware --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Experienced</masterLabel>
            <translation><!-- Experienced --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unaware</masterLabel>
            <translation><!-- Unaware --></translation>
        </picklistValues>
    </fields>
    <fields>
        <help><!-- Yervoy certified (Y/N)? --></help>
        <label><!-- Yervoy certified --></label>
        <name>Yervoy_certified_BMS_CA__c</name>
    </fields>
    <fields>
        <help><!-- What % of 2nd line MM patients may participate in CTrial next 12 months? --></help>
        <label><!-- % of 2nd line MM pts in CTrial --></label>
        <name>of_2nd_line_MM_pts_in_CTrial_BMS_CA__c</name>
    </fields>
    <gender>Neuter</gender>
    <nameFieldLabel><!-- ID --></nameFieldLabel>
    <recordTypes>
        <label><!-- BMS - CAN - Individual - YERVOY Profile --></label>
        <name>BMS_CAN_Individual_YERVOY_Profile</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS Individual - ERBITUX CRC Profile --></label>
        <name>BMS_Individual_ERBITUX_CRC_Profile</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS Individual - ERBITUX H&amp;N Profile --></label>
        <name>BMS_Individual_ERBITUX_H_N_Profile</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS Individual - General Profile --></label>
        <name>BMS_Individual_General_Profile_BMS</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS Individual - IXEMPRA Profile --></label>
        <name>BMS_Individual_IXEMPRA_Profile</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS Individual - Orencia Campaign --></label>
        <name>BMS_Individual_Orencia_Campaign</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - Pharmacist - Post-CRYSTAL Approval Profiling --></label>
        <name>BMS_Individual_Post_CRYSTAL_Approval_Profiling</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS Individual - SPRYCEL Profile --></label>
        <name>BMS_Individual_SPRYCEL_Profile</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS Individual - YERVOY Profile --></label>
        <name>BMS_Individual_YERVOY_Profile</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS Organization - General Profile --></label>
        <name>BMS_Organization_General_Profile</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS Organization - IXEMPRA Profile --></label>
        <name>BMS_Organization_IXEMPRA_Profile</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS Organization (MM) - Approved Sprycel --></label>
        <name>BMS_Organization_MM_Approved_Sprycel</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS Organization (MM) - Eliquis Assessment --></label>
        <name>BMS_Organization_MM_Eliquis_Assessment</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS Organization (MM) - Eliquis Default Coverage Report --></label>
        <name>BMS_Organization_MM_Eliquis_Default_Coverage_Report</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS Organization (MM) - Eliquis Formulary Flash --></label>
        <name>BMS_Organization_MM_Eliquis_Formulary_Flash</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS Organization (MM) - Formulary Flash --></label>
        <name>BMS_Organization_MM_Formulary_Flash</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS Organization (MM) - ORENCIA Profile --></label>
        <name>BMS_Organization_MM_ORENCIA_Profile</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS Organization - YERVOY Profile --></label>
        <name>BMS_Organization_YERVOY_Profile</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - Pathologist - Post-CRYSTAL Approval Profiling --></label>
        <name>BMS_Pathologist_Post_CRYSTAL_Approval_Profiling</name>
    </recordTypes>
    <recordTypes>
        <label>KOL</label>
        <name>KOL</name>
    </recordTypes>
    <recordTypes>
        <label>Oncologie</label>
        <name>Oncology</name>
    </recordTypes>
    <recordTypes>
        <label><!-- UAT Training Survey --></label>
        <name>UAT_Training_Survey</name>
    </recordTypes>
    <validationRules>
        <errorMessage><!-- Survey edit permissions are granted to original author only. Please create a new survey --></errorMessage>
        <name>BMS_Survey_Owneronly_update</name>
    </validationRules>
</CustomObjectTranslation>
